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ABSTRACT 
Pain arising from nerve injury is often resistant to conventional analgesics and is believed 
to have mechanisms distinct from those of nonnal nociception. To determine if spinal 
prostaglandins (pG) contribute to tactile allodynia, male, Sprague-Dawley rats were fitted 
with either i.t. microdialysis or drug delivery catheters 3 days before tight ligation of the 
left lumbar 5/6 spinal nerves. Ligated rats developed tactile allodynia within 24 h, as 
evidenced by a decrease in paw withdrawal thresholds (PWT) in the affected hind paw 
(<4 g vs > 15 g control). Allodynia was also characterized by a significant increase in the 
evoked release of PGE2. Thus, brushing the plantar surface of the affected hind paw with 
a cotton-tipped applicator, up to 5 days post-ligation, increased the CSF level of PGE2 
(measured using intrathecal microdialysis - [PGE2]dialysatc) compared to the pre-stimulus 
control period. In vitro, spinal cord slices were used to detennine the effect of PGE2 on 
glutamate release. The ECso of PGErevoked glutamate release (2.4xlO-1i M; control) 
was significantly decreased in affected spinal segments of allodynic rats (8.9xlO-IS M). 
In a separate group of rats and beginning 2 days after ligation, the acute i.t. injection of 
S(+)-ibuprofen (non-selective cyclooxygenase inhibitor), SC-51322 (prostaglandin E 
receptor antagonist), SC-236 (eyc1ooxygenase-2 selective inhibitor), or SC-560 
(cyc1ooxygenase-1 selective inhibitor) significan1:iy reversed allodynia. The nitric oxide 
synthase inhibitor L-NAME had a similar effect to S(+)-ibuprofen, and was subsequently 
tested using isobolographic analysis. The co-administration of both inhibitors resulted in 
an additive anti-allodynic effect. To investigate spinal PG as possible early triggers of 
allodynia, we studied the effects of early post-injury treatment with isozyme selective and 
non-selective COX inhibitors. Treatment with i.t. S(+)-ibuprofen or SC-560, beginning 2 
h after ligation, prevented the decrease in PWT, the brush-evoked increase in 
[PGE1]ditJ)'Ule' and the change in ECso of PGE2-evoked glutamate release. In contrast, lot. 
R(+ibuprofen or SC-236 had no effect. The results of this study suggest that: a) spinal 
PG synthesis is triggered by spinal nerve ligation; b) pharmacological disruption of PG 
synthesis or signaling can transiently reverse established allodynia; c) spinal PG, 
synthesized by cyclooxygenase (COX)-l in the first 4-Sh after ligation, is a critical 
trigger of allodynia; d) spinal nitric oxide appears to act in concert with PG to mediate 
allodynia. Together, it appears that allodynia resulting from L51L6 spinal nerve ligation 
is comprised of an initial, time-limited, PG-dependent stage (charactcrized by brush-
evoked increases in [PGE2]di.lysate and sensitivity to COX-2 inhibitors) and long-term, 
PG-independent allodynia. The ability of appropriate COX inhibitors to prevent both 
stages suggests that the two are related. 
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1.0 INTRODUCTION 
1.1 NEUROPATHJC PAIN 
Neuropathic pain is defined by the International Association for the Study of Pain 
(lASP) as pain initiated or caused by a primary lesion or dysfunction in the nervous 
system (Merskey and Bogduk, 1994). It is an abnormal sensory state arising from trauma 
or disease affecting peripheral nerves, posterior spinal roots, the spinal cord itself, or 
certain regions of the brain. Examples include phantom limb pain, central post-stroke 
pain, diabetic, alcoholic, nutritional, traumatic or cancerous neuropathy, anterior spinal 
artery syndrome, post-herpetic neuralgia, reflex sympathetic dystrophy, plexus avulsion, 
post-cordotomy dysesthesia, and painful conditions associated with paraplegia and 
multiple sclerosis (Shibasaki and Kuroiwa, 1974; Boivie et al., 1989; Tasker, 1990; 
Portenoy and Hagen, 1990; Tanelian and Brose, 1991; Price et al., 1992; Triggs and 
Beric, 1992; Baron and Saguer, 1993; Portenoy, 2000). Neuropathic pain has also been 
described in several inherited diseases such as Charcot-Marie-Tooth disease (Charcot and 
Marie, 1886; Tooth, 1886), and other hereditary sensory/autonomic/motor neuropathies 
(see review, Kuhlenbaumer et al., 2002). 
The absence of appropriate epidemiological studies makes it difficult to gauge the 
absolute prevalence of neuropathic pain. However, it has been estimated that up to 1.5% 
of the general population are atTected (Chong and Bajwa, 2003). Prevalence also appears 
to vary with the causative event [e.g. post-herpetic neuralgia affects about 10% of all 
patients who contract the disease (Watson et al., 1995») and the age at which nerve injury 
occurs (Beydoun et al., 1999). While a relatively rare and idiosyncratic outcome of nerve 
injury (Noordenbos and Wall, 1981; Arner and Meyerson, 1988; Tasker et al., 1990), 
neuropathic pain can bc extremely debilitating, is often intractable, and represents a 
major burden on the health and social systems (Arner and Meyerson, 1988; Rowbotham 
et aI., 1991; Baron and Saguer, 1993; Schmader, 1998). 
1.2 NEUROPATHIC PAIN DIFFERS FROM NOC ICEPTIVE PAIN 
Neuropathic pain differs from nociceptive pain in several important ways. 
Neuropathic pain is usually chronic in nature, sometimes persisting for years or even 
decades after the initial injury has healed. Its onset is delayed for weeks to months after 
the causative event (Tasker, 1990). For example, 82% of patients with spinal cord 
lesions experienced a delay in pain onset ranging from less than a month to more than 
onc year after injury (Tasker et ai., 1992). The sensations described by patients with 
neuropathic pain are also unique compared to non·neuropathic pain. The pain is 
generally described as a burning, ripping, and/or tearing sensation, yet patients arc often 
unable to identify or locate the inciting stimulus. Radiation of the sensation, abnonnal 
temporal summation, and after·sensations are also frequent sequelae of this syndrome 
(Lindblom and Verrillo, 1979 Noordenbos and Wall, 1981; Price et al., 1992; Kapur, 
2003). 
Another distinguishing feature of neuropathic pain and one of the most significant 
clinical problems is its poor response to current therapy. There remains a diversity of 
opinion on the best therapeutic strategies for treating neuropathic pain (Attal, 2001). 
They include but are not limited to opioid analgesics, tricyclic antidepressants, 
anticonvulsants, barbiturates, local anesthetics and various channel blockers. Therapeutic 
response is highly variable from patient to patient, and rarely do these drug classes effect 
complete pain control, and likewise not all drugs from the same class necessarily show 
efficacy. Surgical interventions, intended to alleviate neuropathic pain, usually provide 
only incomplete and temporary rclief, with the pain eventually returning (Tasker ct aI., 
1992; Eide, 1998). Invasive electrical stimulation of specific spinal, thalamic, or 
sensorimotor cortical regions is another alternative, but this is also variable in outcome 
(Devulder et al., 2002). In short, the majority of patients with neuropathic pain are 
inadequately controlled, making this a serious clinical problem and a major therapeutic 
challenge (Eide, 1998). 
Surveys of patients with neuropathic pain reveal their most common and 
troublesome symptom to be al10dynia (Campbell et aI., 1988; Raja et aI., 1988). 
Allodynia is defined as "pain arising from a stimulus that does not normally evokc pain" 
(Merskey, 1986). Thus, normally innocuous stimuli such as a cold draft of air or the light 
touch of clothing may acquire the ability to evoke excruciating pain after nerve injury. 
Mechanical (tactile) allodynia is the most common type, occurring in 54% of patients 
with central neuropathic pain and 48% of patients with peripheral neuropathic pain 
(Nurmikko and Hietaharju, 1992). It represents the major fonn of allodynia in clinical 
neuropathic pain (Woolf and Doubell, 1994; Ma and Woolf, 1996). 
1.3 ALLODYNIA IS MEDIATED BY AP-FIBERS 
Clinical studies by Campbell et al. (1988) and Price et al. (1989) showed that in 
patients with neuropathic pain, both allodynia in the affected dermatome and the 
sensation of light touch in adjacent normal skin were mediated by the same neural 
elements (Le. A[3-fibers). In contrast, temperature discrimination in the same region was 
unaffected, suggesting little if any involvement of Ao- and C-fibers (Campbell et aI., 
1988). Similarly, conduction velocity for the detection of pain in nerve-injured limbs 
was similar to that for touch in nonnallimbs (Lindblom and Verrillo, 1979; Campbell et 
aI., 1988; Gracely et aI., 1992). Using the spinal nerve ligation model of neuropathic 
pain, Khan et al. (2002) recently showed that rats depleted of C-fibers with 
resiniferatoxin developed tactile allodynia comparable to that in control neuropathic 
animals. Moreover, whereas high-frequency, low-intensity electrical nerve stimulation 
nonnally attenuates clinical nociceptive pain, allodynia is triggered by the same treatment 
(Price et aI., 1992). Neither did transcutaneous electrical nerve stimulation to the affected 
dennatome of nerve-injured rats, using the chronic constriction injury model, mitigate 
mechanical allodynia (Somers and Clemente, 1998). Since A[3-fibers nonnally do not 
evoke pain, their ability to do so after peripheral or central nerve injury implies a change 
in somatosensory processing at the spinal and/or supraspinallevc1. 
1.4 NERVE INJURY INDUCES CHANGES TO THE NERVOUS SYSTEM 
Nerve injury triggers changes in both the peripheral and central nervous system. 
In the periphery, neuromas at the site of nerve transection exhibit increased sensitivity to 
mechanical and thermal stimulation that leads to increased A[3-fiber discharges 
(Babbedge, \996). In the ischemic sciatic nerve injury model, A[3- and Ao-fibers are 
most likely to display spontaneous, ongoing activity (Bulka et aI., 2002). Various ion 
channels, particularly Na + channels, accumulate in the proximal stump of transected 
nerves. Novel Na + channel subtypes have also been identified in these areas, at least one 
of which displays faster recovery than its counterparts (England et aI., 1996). This 
characteristic would facilitate the repetitive firing of injured neurons and represents a 
possible explanation for thc ectopic firing notcd in many sitcs of nerve injury 
(Zimmennann, 2001). Chaplan et al. (2003) recently identified a hyperpolarization-
activated, cation-nonselective, cyclic nucleotide-modulated channel at the site of injury as 
responsible for ongoing activity in Ap- and Ao-fibers. 
Infiltration of inflammatory cells (e.g. macrophages) into myelin lamellae is a 
characteristic of inflammatory neuropathies (Nukada et al., 2000). The development of 
post-ganglionic sympathetic sprouts around type A dorsal root ganglion cells is a feature 
of certain neuropathic pain conditions that are exacerbated by sympathetic nervous 
system activity (McLachlan et al., 1993). Each of these mechanisms has the ability to 
generate sustained excitatory input to the spinal cord which, in tum, induces ccntral 
hyperexcitability; a characteristic feature of hyperalgesic and allodynic conditions 
(Coderre, 1993; see review, Millan, 1999). 
Nerve injury is also known to elicit pronounced changes in the spinal cord. 
Sprouting of large primary afferent (AP) tenninals into lamina I and II of the spinal cord 
has been reported after peripheral nerve transection (Woolf et. aI., 1992). Significant 
losses of opioid binding sites (18-53%) in the superficial dorsal hom were noted in three 
models of peripheral nerve injury (Besse et al., 1992). The up-regUlation of several 
immediate early gene products such as c-fos and c-jun has been shown after nerve injury; 
many of these products are associated with the increased responsiveness of second-order 
neurons (Herdegen et aI., 1992; Molander et aI., 1992). Following nerve ligation, large 
diameter sensory neurons begin to express neurotransmitters normally associated with 
nociceptive transmission (e.g. substance P and brain-derived neurotrophic factor; 
Noguchi et al,. 1994, 1995; Michael el aI., 1999). Spinal afferent terminals have also 
been shown to express novel neurotransmitters such as neuropeptide Y, galanin, and 
vasoactive intestinal peptide after transection, loose ligation, or crushing of the scialic 
nerve (Wakisaka el aI., 1992). 
In an extensive study of spinal inhibitory mechanisms, Moore et al. (2002) 
reported that GABAA receptor-mediated inhibitory postsynaptic currents (lPSCs) were 
decreased in two partial nerve injury models compared to naive animals. Analysis of 
unitary IPSCs suggested that presynaptic GABA release was reduced following chronic 
constriction- or spared nerve-injury. Moreover, there is recent evidence that 
glycinergic/GABAergic transmission can change from an inhibitory to an excitatory 
nature after nerve injury (Coull et aI., 2003). Partial nerve injury induced neuronal 
apoptosis and decreased dorsal horn levels of glutamate decarboxylase (GAD65) 
ipsilateral to the injury (Moore et aI., 2002). This builds upon earlier reports 
demonstrating the appearance of dark staining dorsal horn neurons (presumed to be 
deteriorating interneurons) after chronic constriction injury (Sugimoto et aI., 1989; 1990; 
Mayer et ai., 1999). 
These presynaptic and postsynaptic changes suggest a major reorganization of 
spinal cord connections andlor nerve function after nerve injury, and are directly or 
indirectly correlated with the development of various types of hypersensitivity in the 
spinal cord (see review, Millan, 1999). Although the functional significance of these 
changes with neuropathic pain remains to be determined, it is clear that the spinal cord is 
a major site of injury-induced adaptation and represents an obvious target for the 
treatment of neuropathic pain. 
1.5 PROSTAGLANDIN SYNTHESIS 
Prostaglandins belong to a family of lipid mediators derived from arachidonic 
acid, a 20-carbon fatty acid. They are not previously generated and stored in secretory 
granules but rather are synthesized de novo. The initial step in the biosynthesis of 
prostaglandins is the liberation of arachidonic acid from phospholipid membranes (Smith, 
1992). This is commonly mediated by the phospholipase A2 (PLA2) family. 
Phospholipase C and D can have similar actions but their mechanisms differ from that of 
PLA2 (Smith, 1992). Broadly, there are two subgroups within the PLA2 family; a 
secretory (sPLA2) and a cytosolic (cPLA2) form. Expression of the former is induced by 
pro-inflammatory cytokines and inhibited by glucocorticoids. Secretory PLA2 has been 
shown to have similar transcriptional regulation as other enzymes in the prostanoid 
synthetic pathway such as COX-2 (Murakami et aI., 2000). Cytosolic PLA2 appears to be 
involved in the generation of lipid mediators immediately following cell activation. 
Calcium-dependent translocation of cPLA2 and subsequent binding to phospholipid 
membranes are required for enzymatic activity, often binding to the nuclear envelope or 
the endoplasmic reticulum - two common locations for the cyclooxygenases, 
lipooxygenases, and tenninal PG synthases (Leslie, 1997; Murakami ct aI., 2000). 
Once released from the lipid membranes, arachidonic acid is acted upon by 
cyclooxygenases (prostaglandin synthases) - this represents the first committed step in 
prostanoid synthesis. Cyclooxygenase is a bifunctional enzyme that initially converts 
arachidonic acid to PGGz. The same enzyme subsequently catalyzes this intermediate to 
PGHz via its peroxidase activity (see review, Smith et aI., 2000; and section 1.6 for more 
detail). Specific synthases then utilize PGHz as a precursor to produce the most 
important biologically active products: PGD2. PGEz, PGFz, PGlz, and TxAz (Hara et aI., 
1994; Kuwamoto et aI., 1997; Suzuki et aI., 1997; Jakobsson et aI., 1999). These are then 
free to diffuse out of the cell, or exit by means of a carrier·mcdiated process (Chan et aI., 
1998) and bind to prostanoid·specific receptors on the cell surfaces (Ushikubi et aI., 
1998; Sugimoto et aI., 1998; Murata et aI., 1997; also see review, Breyer et al.. 2001) or 
to nuclear receptors (Lim ct ai., 1999; Kliewer ct ai., 1997; also see review Negishi et ai., 
1995). 
While cyclooxygenase is inactivated during catalysis by suicidal inactivation, the 
biological relevance of this inactivation is unclear. The levels of COX normally exceed 
substrate concentration, and bursts of prostanoid synthesis do not result in a overall 
decline in COX activity. However, many agents that stimulate arachidonic acid release 
also initiate transcription ofCOX·2 (DeWitt, 1991). Transcription of the COX·2 gene is 
similar to that of highly regulated gene products, and contains promoter regions and 
transcription binding sites that can be activated immediately in response to external 
stimul i (Yamamoto et aI., 1995). In contrast, the promoter region of the COX·I gene has 
many characteristics of a housekeeper gene. Consistent with this observation is the fact 
that COX·I mRNA and protein are expressed in most tissues under basal conditions and 
do not vary greatly (Wang et aI., 1993). It is presumably through these mechanisms that 
cells are able to regulate COX levels, control prostaglandin synthesis, and prevent the 
exhaustion ofprostanoid generating capacity in the face of chronic stimulation. 
1.6 CYCLOOXYGENASES AND SPECIFIC PROSTAGLANDIN SYNTHASES 
Prostaglandin endoperoxide H synthase (commonly known as eyclooxygenase) 
was purified in 1976 and cloned in 1988. This enzyme is the key catalytic protein in the 
synthesis of prostaglandins from arachidonic acid, and is subject to inhibition by non-
steroidal anti-inflammatory drugs (NSAIOS). In 1991, several laboratories identified a 
second gene product with COX activity, now termed COX-2. It is clear now that both 
isoforms, COX-I and COX-2 are expressed in both peripheral tissues and several areas of 
the eNS (see reviews: Vanegas and Schaible, 2001; Kaufmann et al., 1997; Vane et al., 
1998). 
Both isoforms are membrane-associated enzymes having a molecular weight of 
71 kD. Each exists as a homodimer, composed of three independent folding units: the 
active enzymatic domain within a long hydrophobic channel, a membrane-binding 
domain, and an epidermal growth factor-like domain (see review: Smith et al., 2000). 
They exhibit 60-65% amino acid sequence homology within the same species. Within 
each isoform, there is 85-90% homology across species. The most striking differences in 
amino acid sequence oceur within the membrane-binding domains (Otto and Smith, 
1996; Spencer et al., 1999). Each enzyme has two catalytic activi tics. The 
cyclooxygenase reaction occurs within a hydrophobic channel where arachidonic acid 
plus two molecules of oxygen are convertcd to PGG2. Peroxidase activity, occurring at a 
separate site, leads to the reduction ofPGG2 to PGH2. 
Initially, COX-l and COX-2 were thought to subserve physiological and 
pathophysiological functions, respectively. However, it is now recognized that both 
isofonns can fulfill either role, depending on the cell type and the prevailing conditions. 
For example, while COX-2 seems to be clearly involved in inflammatory responses and 
nociception, this isofonn, along with COX-I, is also important in the homeostatic 
regulation of kidney function. A related over-simplification is their classification as 
either 'constitutive' or 'inducible'. Although COX-I is nonnally present at a constant 
level in the cell types examined to date, and COX-2, which is often absent from several 
cell types, can rapidly be upregulated, there are exceptions. A notable example is the 
recent study by Zhu et al. (2003) who reported an increase in COX-I immunoreactivity in 
glia of the dorsal hom and gracile nucleus in a post-operative pain model. 
Conversion of the unstable endoperoxide intennediate PGH2 to biologically-
active prostaglandins is perfonned by cell-specific tenninal prostaglandin isomerases and 
synthases. Individual enzymes exist for the conversion of PGlh to each class of 
proslanoid (e.g. PGD synthase converts PGH2 to PGD2). 
A newly discovered variant of the cyclooxygenase fami ly (so-called COX-3) is 
currently the subject of investigation. It was first reported by Chandraskharan et al. 
(2002) who described the presence of COX-3 mRNA in canine and human tissues, 
especially in the brain. This novel isofonn may be a splice variant of COX-I as it shares 
similar molecular properties with COX-I. Interestingly this study, and subsequent work 
by Ayoub et al. (2004), suggests that COX-3 (or some variant of COX-I) may be a target 
for acetaminophen. This may explain the disparity of actions observed with this drug. 
Since the first reports of COX-3 mRNA in canine and human tissue, COX-3 mRNA has 
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also been identified in rat and mouse CNS (Shaftel et aI., 2003; Kis et aI., 2004). 
Whether COX-3 mRNA actually encodes a protein capable of converting arachidonic 
acid to prostaglandins, and is thus a target for some NSAID drugs, remains to be 
elucidated (Dinchuk et aI., 2003). 
1.7 IMPORTANT COX PRODUCTS AND THEIR TARGETS 
Prostaglandins are a family of autacoids comprising five primary biologically-
active compounds: PGD2, PGE2, PGF2(1, PGI2, TXA2 (see review, Smith, 1992). The first 
four are important in nociception. Because they are either chemically unstable or 
undergo rapid metabolism in vivo, prostanoids are thought to act locally, close to their 
site of production. Their biological actions are thought to be mcdiated by specific 
receptors corresponding to their prostanoid classification: prostaglandin D receptor (DP), 
prostaglandin E receptor (EP), prostaglandin F receptor (F P), prostaglandin I receptor 
(IP), and thromboxane A receptor (TP). The EP class is further subdivided into EP 1, EP2, 
EP) and EP4 subtypes (Coleman et aI., 1990, 1994). Several splice variants have also 
been identified for the EPI, EP3, FP and TP classes, although the variation appears to be 
with in the intracellular C-terminal region which does not seem to affect ligand-binding 
properties. Rather, this variation may affect G-protein coupling speci fi ci ty, constituti ve 
activity, and agonist-induced receptor phosphorylation, desensitization, and/or 
internalization. While each prostaglandin binds with highest affinity to its cognate 
receptor, considerable cross-reactivity has been observed between a particular 
prostaglandin and other prostaglandin receptors (see reviews: Breyer ct aI., 2001; Wise et 
aJ.,2002). 
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Prostaglandin receptors are coupled to G-proteins and thus have the usual seven-
transmembrane-region architecture. They belong to family A G-protein coupled 
receptors and have been categorized into group V of this family according to 
phylogenetic examination. Group V also includes receptors for pituitary honnones and 
opioids. Prostaglandin receptors have the closest relation to the vasopressin receptor 
family. Within the prostaglandin receptor family, only about a 20-30% amino acid 
sequence homology exists, mostly found within the transmembrane regions. 
1.7.1 PGD! AND DP RECEPTORS 
A role for PGD2 has been demonstrated in the sleep-wake cycle (Urade and 
Hayaishi, 1999), body temperature regulation (Sri Kantha et aI., 1994), and mast cell 
activity (Lewis et aI., 1982). PGD2 also effects vasodilation, vasoconstriction, and the 
inhibition of platelet aggregation (Giles et ai., 1989). Among the prostaglandin receptors, 
the DP receptor is the most recent to be cloned, and consequently the least characterized. 
Quantitatively, it also seems to be the least expressed. DP receptor mRNA is generally 
expressed in low levels, except in tissues like the retina and mucus-secreting cells of the 
GI tract (Hirata et aI., 1994). DP receptor mRNA is also found in sensory and motor 
neurons in the rat spinal cord, suggesting some modulatory role of these functions 
(Wright et ai, 1999). In the brain, DP receptor mRNA and protein have been localized in 
areas thought to be important in sleep. Thus, the infusion of PGDz into these areas, 
particularly the subarachnoid space below the basal forebrain, has been shown to induce 
sleep in experimental animals (Scammell et aI., 1998). 
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The DP receptor class is coupled to Gs protein and is positively-coupled to 
adenylyl cyclase. The Ki value for PG~ at the DP receptor has been reported to be 21 
nM using transfccted CHO cells (Kiriyama et al. 1997). 
1.7.2 PGEl AND EP RECEPTORS 
Prostaglandin E2 is the major product of COX-mediated arachidonic acid 
metabolism. Among all the prostanoids, PGE! exhibits a wide spectrum of physiological 
and pathophysiological roles. Many of these are apparently opposing actions. One 
example is on smooth muscle, where POE2's vasodilatory effect in both arterial and 
venous beds is well known. However, POE2 can induce powerful contractile responses in 
smooth muscle of the trachea and sections of the 01 tract (Lydford et aI., 1996; Coleman 
el aI., 1990). That some structural analogs of POE2 can replicate the vasoconstrictor 
effect, but not the vasodilator action in other tissues where this effect is known to occur 
(the converse of this is also true), provides important functional evidence of subclasses of 
the EP receptor. POE! can also stimulate or inhibit neurotransmitter release, and sodium 
and water reabsorption in the kidney providing further evidence for EP receptor 
subclasses and their distinct coupling to signal transduction pathways (Negishi et aI., 
1995). 
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1.7.2.1 EP I RECEPTORS 
The distribution of EP1 receptors is more restricted than the other EP classes. EP1 
mRNA has been identified in mouse kidney, lung, and stomach, where PGEz has been 
implicated in the regulation of water reabsorption and smooth muscle contraction 
(Watabe et aI., 1993; Sugimoto et aI., 1994). Within the eNS, EP1 mRNA is localized in 
neurons of the thalamus (Y. Sugimoto, unpublished observations; see review, Narumiya 
et aI., 1999), and in DRG cells (Oida et al., 1995). Signal transduction of EP1 receptors is 
unclear, most likely because of the existence of splice variants in this subclass and the 
suggestion that these variants differ in their signaling pathways (Okuda-Ashitaka et ai., 
1996). While activation of human EP1 receptors leads to increased IP) and [Caz+];, mouse 
EP 1 receptors mediate increases in [Caz",]; with little increase in 1P3 but require 
extracellular Ca2+. These results suggest the lack of involvement of a Gq G-protein 
(Watabe et a!., 1993; also see review, Narumiya et aI., (999). The exact G-protein to 
which the EP 1 receptor is coupled remains unclear. What is clear is that PGE2 can induce 
increases in [Cazl, via the EP 1 receptor. 
1.7.2.2 EPz RECEPTORS 
Although EP2 receptors are the least abundant of the EP subclass, they can be 
upregulated in the face of certain stimuli (e.g. LPS application to macrophages) 
(Katsuyama et aI., 1998). They are absent from many tissues, including the uterus, but 
are upregulated there during pregnancy. Receptor density peaks during blastocyst 
implantation suggesting physiological importance in Ihis biological process (Katsuyama 
et aI., 1997; Hizaki et al., 1999). EPz receptors mediate relaxation of airway smooth 
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muscle, and selective agonists were considered as anti-asthmatics (Coleman et ai., 1994; 
Pavord et aI., 1991). In the spinal cord, EP2 receptor mRNA is present in neurons and 
endothclial cclls of the dorsal and ventral horns (Kawamura et al., 1997). 
EP2 receptors are positively coupled to adenylyl cyclase as evidenced by a 7 I-fold 
increase in intracellular cyclic AMP concentration ([cAMP];) following application of 1 
J.lM PGE2 to in EP2-transfected human embryo kidney (HEK) cells as compared to 
untransfected cells (Fujino et ai., 2003). This effect on cAMP is in agreement with the 
ability ofPGE2 to relax smooth muscle. While the EP4 subclass exhibits agonist-induced 
desensitization, possibly due to phosphorylation of its C-terminal sequence, no such 
desensitization was noted with the EP2 receptor (Nishigaki et aI., 1996). 
1.7.2.3 EP) 
EP3 and EP4 receptors are the most widely distributed subtypes within the EP 
class. Their mRNA has been identified in almost all mouse and human tissues examined, 
including kidney, uterus, adrenal gland, and stomach (Sugimoto et aI., 1992; see also 
review Breyer et al., 2001). In situ hybridization studies in the kidney have shown EP) 
mRNA to be present in the outer medulla, thick ascending limb and cortical collecting 
ducts (Sugimoto et aI., 1994a). These are probably responsible for mediating the 
regulatory effect of PGE2 on ion transport. Similar distribution patterns were found in 
the human kidney (Breyer et al., \996). The density of EP3 receptors in the mouse uterus 
appear to be under considerable endocrine control, especially during early slages of 
prcgnancy. This suggests their importance in fertilization and implantation (Katsuyama 
et al., 1997). In the mouse, EP) mRNA is most abundant in the brain (Sugimoto et aI., 
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1992) where it is found in neurons of the cortex, hippocampus, thalamus, hypothalamus, 
midbrain and lower brain stem (Sugimoto et aI., 1994b). In the hypothalamus, EP3 is 
expressed in the organum vasculosa lamina tenninalis, a structure with a poor blood-
brain bamer. As a result, it is more sensitive to factors in the peripheral circulation. 
Here, EP] receptors are believed to be responsible for the febrile response to PGE2. Mice 
lacking this receptor exhibit a diminished febrile response (Ushikubi et aI., 1998). 
Monoaminergic neurons arising from brainstem centers such as thc locus ceruleus, 
substantia nigra and raphe nuclei also express EP3 receptors. Their activation is thought 
to modulate the autoregulation of these cells. Momiyama et al. (1996) demonstrated the 
membrane-depolarizing effects of EP3 receptor agonists on large serotonergic neurons in 
the dorsal raphe. 
EP] mRNA has also been identified in ORO cells, where about half of all neurons 
(but not glia) were EP3 positive. These were primarily small neurons suggesting a role 
for EP) receptors in POE2-mediated hyperalgesia (Oida et aI., 1995; Sugimoto ct aI., 
1994b). Many EP3-positive DRO cells also express IP receptors (Oida et aI., 1995). EP3 
receptor mRNA is also found in laminae I and II cells of the spinal dorsal hom, and on 
branches extending into deeper laminae (e.g. V; Beiche et aI., 1998). 
Because of splice variants in this receptor subclass (thcre arc 4 major variants: 
EP3A.O), the signal transduction pathways to which EP3 receptors are coupled is not as 
clear as other PO receptors. The major pathway for EP] is the inhibition of adenylyl 
cyclase via a Oi-protein. Other variants utilize different signaling mechanisms (EP1A 
inhibit adenylyl cyclasc via Oi; EP1B and EP3C activate adenylyl cyclase via Gs). The 
EP3D variant is unusually complex exhibiting coupling to Oq-, Oi- and Gs-proteins. and 
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can evoke a pcrtussis-toxin insensitive increase in phosphatidylinositol (Namba et at, 
1993). 
1.7.2.4 EP4 
In the mouse, EP4 mRNA has been identified in most tissues studied, including 
the kidney glomerulus where it is thought to mediate the regulation of glomerular 
filtration by PGE2 (Sugimoto et at, 1994). EP4 mRNA is also found in neurons of the 
hypothalamus and lower brain stem (Y. Sugimoto, unpublished obsctvations; see review, 
Narumiya et at, 1999), as well as in about 20% ofDRG cells (Oida et al., 1995). Some 
of the latter cclls also co-express IP receptors. EP4 receptors, like the EP2 and EPJ 
subtypes, are expressed in the uterus, particularly the endometrium where their density 
can change significantly during the early stages of pregnancy (Katsuyama et al., 1997). 
The EP4 reccptor is coupled to adenylyl cyclase via a Gs-protein. Whi le the EP2 
and EP4 receptors share the same signaling pathway, the latter appears to be less-
efficiently coupled. The increase in cAMP following EP4 receptor activation with PGE2 
was significantly less than at EP2, despite the higher affinity ofPGE2 for the EP4 receptor 
(Fuji no el aI., 2003). The basis of this difference remains unclear. The EP4 receptor may 
also play an important role in gene regulation (Fujino el al., 2003) through a separate 
(cAMP-independent) transduction pathway. This appears to be a phosphatidylinositol 3-
kinase dependent pathway involving extracellular signal-regulated kinases and early 
growth response factor-l (Fujino et at, 2002). 
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1.7.3 PGFza AND FP RECEPTORS 
PGF2a was one of the first prostaglandins identified effecting potent constriction 
of vascular and non-vascular (e.g. bronchial) smooth muscle. PGF2a plays a major role in 
female reproduction, being released from the endometrium, promoting luteolysis in 
several animal species, and causing regression of the corpus luteum. Its biological effects 
are mediated by the FP receptor whose tissue distribution has been less well studied than 
other prostaglandin receptors. To date, FP mRNA is most highly concentrated in the 
corpus luteum (Hasumoto et aI., 1997). Its expression varies throughout the estrous 
cycle, suggesting a functional relationship between FP gene expression and luteolysis. 
This is in line with reports that FP receptor expression is critical for normal birth in miee 
(Sugimoto et aI., 1997). FP mRNA is also present in the kidney, hean, lung, and stomach 
where its expression is stable throughout estrous (Kitanaka et al., 1994). Expression in 
the CNS has not been clear, but FP receptors have been dctected in aSlrocytes (Negishi et 
al.,1995). FP receptors arc coupled to a Gq -protein and linked to the activation ofPLC 
(Ito et aI., 1994). Interestingly, PGF2a induced DNA synthesis in NIH 3T3 cells via the 
same FP receptor-effector pathway (Watanabe et al., 1994). 
1.7.4 PGh AND IP RECEPTORS 
PGh, also known as prostacyclin, was originally derived from the vascular bed 
and identified as a vasodilator and inhibitor of platelet aggregation (Moncada et aI., 
1976). Endothelial cells are a major source of PGh where it is responsible for vascular-
related effects such as vasodilation and anti thrombosis (Murata et a1., 1997; Hoeper et aI., 
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2000). These biological effects directly oppose those of TXA2 making PGlz an important 
factor in the maintenance of circulatory homeostasis. 
Mouse IP receptor mRNA has been identified in several tissues, including arterial 
smooth muscle and the kidneys, particularly the glomerular afferent arterioles, where 
PGb is known to serve important physiological functions (Oida et aI., 1995). However, 
IP mRNA is found most abundantly in ORO cells where it is co-localized with the 
mRNA of a substance P precursor (Oida et aI. , 1995). In some ORO cells, IP receptor 
mRNA is co-expressed with mRNA of the EP receptor subtypes, suggesting possible 
overlap with the EP receptors, or perhaps a distinct role of IP receptors in pain 
transmission. IP mRNA was absent in glia of the ORO, and in neurons and glia of the 
spinal cord (Oida et aI., 1995). PGh binding sites have been identified in the superficial 
laminae of the spinal dorsal hom using autoradiography, consistent with a role for PGh 
in pain signaling (Matsumura et ai, 1995). 
The IP receptor is known to activate adenylyl cyclase leading to increased cAMP 
production, as well as PLC via a Gq protein (Namba et aI., 1994). The ability of the IP 
receptor to couple to different types of G-proteins based on cell type may explain the 
diverse biological actions of PGIz. 
1.8 CYCLOOXYGENASES AND PROSTAGLANDIN RECEPTORS ARE 
LOCALIZED IN THE SPINAL CORD 
The concept that prostaglandins are synthesized in the CNS was strengthened by 
reports that COX is present in the brain and spinal cord. COX- I and COX-2 mRNA and 
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protein arc constitutively expressed in many regions of the CNS, including the dorsal and 
ventral grey matter of the spinal cord, as well as in the periphery in dorsal root ganglia 
(DRG). Immunocytochemical and autoradiographic studies confinned the presence of 
COX-l in spinal nociceptive pathways (Goppelt-Struebe et aI., 1997; Willingale et aI., 
1997; Seiche et aI., I 998a,b). COX-2-LI is present in neurons throughout the spinal cord, 
and is especially abundant in the superficial dorsal hom where the nociceptive primary 
afferent fibers are known to tenninate. The presence of COX-I in neurons is more 
controversial but COX-I immunoJabeUing was recently described in a subpopulation of 
putative nociceptive DRO neurons (Chopra et aI., 2000). COX-I and COX-2 are also 
expressed in astrocyles (Vane et aI., 1998). 
Cyclooxygenase in the spinal cord is subject to induction. A 2-fold increase in 
COX-2 mRNA and a smaller increase in COX-2 protein was detected bilaterally in the 
lumbar spinal cord of the rat following acute carrageenan-induced, peripheral 
inflammation (Ooppelt-Struebe et aI., 1997; Ichitani et aI., 1997; Hay and de Belleroche, 
1997). Western blot analysis revealed a 1.6-fold increase in the level ofCOX-2 protein 
in the lumbar dorsal hom (lamina II-III) 22 days after the onset of adjuvant-induced 
arthritis in the rat (Goppelt-Struebe et aI., 1997; Seiche et a\., 1998a,b). Samad et al. 
(2001) reported a peak increase (l6-fold) in COX-2 mRNA 6 h after CFA injection in the 
ipsilateral hind paw. Bilateral induction was noted 12 h after injection. Increases in 
COX-2 protein were also noted in the same animals. The increased expression ofCOX-2 
is both neuronal and non-neuronal in nature (Samad et al., 2001; Beiche el al., 1998a,b; 
MaihOfner et aI., 2000; Tegeder et aI., 2001). Where investigated, these increases 
coincide wi lh a significant elevation in spinal prostanoid concentration. These results 
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suggest that COX-2 is inducible and is likely responsible for the increase in spinal 
prostaglandin synthesis and release during peripheral inflammation. 
The localization of COX in the dendrites of central excitatory neurons supports a 
role for prostaglandins in the modulation of synaptic signaling (Yamamoto. 1993). This 
hypothesis is further supported by the abundance of PGE2 binding sites in the spinal 
dorsal hom (Matsumura. 1992; 1995). These appear to bc locatcd on thc tcrminals of 
primary afferent fibers as the density of these binding sites almost completely 
disappeared after dorsal rhizotomy. The density on the operated side was only 4 ± 4% of 
the control sidc 8 days aftcr surgery (Matsumura. 1995). This pattern of PGE2 
rcceptor-binding is consistent with the presynaptic facilitation of neuronal signaling. 
In summary. there is substantial evidence that prostaglandins are synthesized and 
released in the spinal cord in response to nociceptive input. The temporal correlation of 
this central biochemical process with nociceptive behavior and peripheral inflammation 
indicates that spinal prostaglandins may bc critical in thc induction of a central pain slate 
at the spinal level. 
1.9 CELLULAR EFFECTS OF SPINAL PROSTAGLANDINS IMPORT ANT IN 
NOCICEPTION 
The exact mechanisms by which central prostaglandins enhance nociceptive 
signaling have yet to be elucidated. One strong possibility is that prostaglandins exert 
their effects through excitatory receptors on primary afferent terminals that form synaptic 
connections with second order neurons andlor excitatory intemeurons in the dorsal hom 
(see review, Millan, 1999). Using cultured avian neurons, Nicol et al. (1992) showed that 
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1 flM POE2 yielded a 2-fold increase in substance P release; 5 flM POEz resulted in a 4-
fold increase similar to that evoked by 50 mM KCI. In the same study, I flM POEz 
produced a lA-I.8 fold increase in Ca2+ current. Whole-cell patch clamp recordings of 
rat embryonic sensory neurons revealed a significant decrease in outward K+- current 
foJ1owing exposure to POEz (Nicol et ai., 1997). Oold et al. (1996) reported that POEz 
increased tetrodotoxin-resistant Na+- currents recorded from cultured ORO cells; an effect 
shared by other hyperalgesic agents. These ion channel effects would result in an overall 
increase in cell excitability and enhance the chance of cell firing. 
POEz has also been shown to evoke Caz+-dependent glutamate release from 
synaptosomes prepared from rat spinal cord (Nishihara, 1995), and substance P release 
from cultured rat ORO cells (Vasko, 1994) and rat spinal cord slices (Vasko et aI., 1995). 
The effect of POEz on substance P release was inhibited by the selective EP I receptor 
antagonist, SC-19220, and by guanosine-5'-[beta-thio] diphosphate, an inhibitor of 
stimulatory O-protein (Os) to which the EP I receptor is coupled (Cui ct al., 1995; White 
et ai., 1996). Conversely, guanosine-5'-[gamma-thio] triphosphate, an activator of Os 
protein, enhanced POEz-evoked release of substance P. Perfusion with low 
concentrations of POEz has also been shown to facilitate capsaicin- or bradykinin-evoked 
release of substance P or CGRP from rat spinal cord slices (Hingtgen et aI., 1995; Vasko 
ct aI., 1995). Collectively, these results indicate that POE2, acting through 
G-protein-coupled receptors, can directly effect neurotransmitter release from the spinal 
cord, as well as augment the release of neuropeptides from the spinal tenninals of C-
fibers evoked by known algogenic agents. 
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Prostaglandins may also enhance the excitability of dorsal hom neurons to 
atTerent input through a direct postsynaptic etTect. In an early study, microiontophoretic 
application of POE) onto motor neurons and intemeurons in the isolated spinal cord of 
the frog produced an abrupt excitatory effect (Coceani et aI., 1975). More recently, PGE2 
was shown to induce a long-lasting facilitation of evoked excitatory postsynaptic currents 
(EPSCs) in mouse dorsal hom neurons (Minami et aI., 1999). Baba et al. (2001) showed 
that the inclusion of PGE2 in the bath caused a direct activation of dorsal hom neurons in 
vitro. They concluded that this was a post-synaptic effect, and probably mediated 
through the prostaglandin EP2 receptor subclass. The "wind-up" of a spinal C-fiber 
nociceptive reflex, induced by repeated electrical stimulation of the sural nerve, was also 
dose-dependently inhibited by Lt. or i.v. indomethacin, and by i.v. administration of the 
selective COX-2 inhibitor, SC-58125 (Bustamante et al., 1997; Willingale et aI., 1997). 
While these studies do not preclude a change in neuronal excitabili ty secondary to an 
increase in glutamate and neuropeptide release, they do provide further support for the 
positive modulatory effect of prostaglandins on spinal neurotransmission. 
1.10 EVIDENCE FOR THE ROLE OF PROSTAGLANDINS IN NORMAL PAIN 
AND HYPERALGESIA 
Prostaglandins have long been linked to hyperalgesia and pain (see review, Lim, 
1970). Indeed, early work by Vane (197 1) and Smith and Willis (1971) suggested that 
non-steroidal anti-inflammatory drugs (NSAIDs) effect their analgesic and anti-
h}'pCralgesic actions through the inhibition of peripheral prostaglandin synthesis. Later 
work by Yaksh and Malmberg (1993) pointed to a spinal site of action, in addition to, but 
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independent of, the more well-known role of peripheral prostaglandins in pain and 
inflammation. 
The synthesis of prostaglandins within the central nervous system (CNS) in 
response to repeated C-tiber activity was first reported by Malmberg and Yaksh (l992a; 
also see McConnack I 994a,b for review). It was based on the observation that NSAIDs, 
injected directly into spinal subarachnoid space of conscious rats, dose-dependently 
inhibited the behavioral responses triggered by fonnalin injection in the fool pad 
(Malmberg and Yaksh, 1992a). When given spinally, NSAIDs were 100-1000 times 
more potent than systemic administration in inhibiting the second phase of the fonnalin 
test (Malmberg and Yaksh, 1992a). The antinociceptive effect ofi.t. ibuprofen was also 
stereospecific (Malmberg and Yaksh, 1995a). IntrathtX:al NSAIDs inhibited glutamate-
or substance P-induced hyperalgesia in the rat (Malmberg and Yaksh, 1992b), and 
reduced the spinal release of substance P and CGRP (Southall et al., 1998). These results 
strongly support a spinally mediated antinociceptive effect attributable to local COX 
inhibition. 
That spinal prostaglandin synthesis is evoked by high-threshold (i.e. nociceptive) 
input was subsequently continned in vivo and in vitro. Using an Lt. microdialysis 
catheter, Yang et al. (1996) showed that the injection ofcarrageenanlkaolin into the knee 
joint of the rat evoked persistent nociceptive behavior and a time-dependent increase in 
the concentration of PGE2 in spinal dialysate (146 ± II % and 143 ± 18% above baseline 
10 min and 24 h after injection, respectively). An increase in PGE2 concentration (109 ± 
10% and 83 ± 15% above baseline) was also reported during the first- and second-phase 
of the rat fonnalin test (Malmberg, 1995a,b); an effect triggered by C-fibcr input (Hua et 
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aI., 1997). Both nociceptive behavior and the increase in the PGE! concentration were 
attenuated by i.t. S(+)-ibuprofen, but not the inactive R(-)-enantiomer (Malmberg, 1995b; 
Yang, 1996). Intrathecal substance P, which induces hyperalgesia in the rat, also elicits a 
dramatic increase (362 ± 37% of baseline) in PGE! concentration in spinal CSF (Hua et 
ai.,1999). 
Using an in vitro spinal superfusion model, Dirig et al. (1999) showed that spinal 
cords harvested from rats pretreated with kaolin/carrageenan in the knee joint for 5-72 h 
exhibited increased release ofPGE! compared to control. Further increases were induced 
with substance P (0.1-1.0 11M) or capsaicin (0.1-10 11M). These results indicate that 
spinal PGE2 synthesis can be triggered by peripheral inflammation, or by directly 
exposing the cord to receptor ligands released in the CNS in response to peripheral 
inflammation. 
LIt CENTRAL PROSTAGLANDINS AND ALLODYNIA 
The ability of prostaglandins to sensitize spinal cord neurons to high-threshold 
(C-fiber) somatosensory input raises an important question about their possible role in 
abnormal pain states. For example, do low threshold mechanoreceptive (AP) primary 
afferent fibers activate spinal prostanoid-mediated sensitizing mechanisms in allodynia? 
In turn, can central prostaglandins, synthesized in response to spinal or peripheral nerve 
injury, affect low-threshold input in a way that miscodes it as pain? 
The most direct evidence supporting a role for prostaglandins comes from the 
studies of Uda et al. (1990) and Minami et al. (1992, 1994a, 1995a) who showed that the 
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i.t. injection of PGE2, PG02 or PGF~ in conscious mice elicited dose-dependent, touch-
evokcd agitation. The effect induced by PGE2 was blocked by the receptor antagonist, 
NON-NT-DI2, suggesting that this was mediated by spinal EP I-receptors (Minami et al. 
1995b). Similarly, the delivery ofPGE2 through a microdialysis probe implanted in the 
spinal subarachnoid space of rats triggered an immediate increase in the concentration of 
glutamate, aspartate, taurinc, glycine and GABA in dialysate samples (Malmberg and 
Yaksh, I 995a). These neurochemical responses were temporally correlated with the 
onset and deeline of behaviorally-defined allodynia (Malmberg and Yaksh, 1995a). In 
the same study, the combination of PGE2 (10 ~M) and capsaicin (D.I or 1.0 ~M), 
concentrations that individually had no effect on neurotransmitter release, evoked a 
significant increase (60-100%) in the dialysate concentration of glutamate, aspartate, 
taurine, glycine and GABA, as well as tactile allodynia. These results indicate that 
introducing exogenous prostaglandins into the spinal subarachnoid space of otherwise 
normal animals induces short-term neurochemical and bchavioral effects indicative of 
allodynia, and is consistent with the hypothesis that spinal prostaglandins contribute to 
the development of tacti le allodynia in nerve injured animals. 
Conversely, i.t. kctorolac or S(+)-ibuprofcn suppressed the hair deflection-evoked 
neurochemical (i.e. increased catechol oxidation current in the locus coeruleus) and 
physiological (i.e. increased heart rate and blood pressure) responses in i.t. strychninc-
treated rats (Hall et al.. 1999). The inactive R(-) isomer of ibuprofen was without effect 
suggesting this attenuation was rclated to the inhibition of COX isoforms in the spinal 
cord. In a related disinhibitory model of allodynia (spinal bicuculline), focal application 
of the COX-2 inhibitor. NS-398. or the EP receptor antagonist, SC-51322. to the dorsal 
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surface of the rat spinal cord produced a highly localized anti-allodynic effect (Zhang et 
al.,2001). Intrathecal ketorolac (20 nmoles) also reduced thermal hyperalgesia and cold 
allodynia in the chronic constriction injury model (Parris et aL, 1996). 
Messenger RNA hybridization analysis reveals a 3-fold increase in COX-2 
mRNA in the rat lumbar spinal cord compared to control 2-4 h after the unilateral 
intraplantar injection of Freund's complete adjuvant (FCA; Hay et aL, 1997). This was 
accompanied by a significant, but delayed, increase (peak effect 8 h after FCA) in the 
spinal concentration of 6-keto PGF] and PGE2. All changes were temporally correlated 
with a decrease in the weight-bearing capacity of the affected paw (a quantitative 
measure of allodynia). The s.c. administration of indomethacin, or the COX-2 selective 
inhibitor, flosulide, attenuated the increase in spinal prostaglandin concentration, and 
inhibited allodynia by 80-100%. Neither drug had any effect on mechanical hyperalgesia 
(Hay et aI., 1997). Collectively, these studies provide convincing evidence that spinal 
prostaglandins contribute to the development of allodynia whether induced by peripheral 
inflammation, central disinhibition, or direct nerve injury. 
1.12 PROSTAGLANDINS AND NEUROPROTECTION 
While the role of prostaglandins as mediators of inflammation and normal 
nociception is well established, their role(s) in initiating mechanisms that lead to more 
permanent pathologies is less clear. However, there is growing evidence, including 
studies demonslIating the protective effects of COX inhibitors, that prostaglandins may 
indeed play such a role. For example, the application of LPS to a neuronal-glial culturc 
induced neuronal loss in a dose-dependent manner as evidenced by decreased MAP-2 
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positive cells (an immunohistochemical marker of mature neurons) and the emux of 
lactate dehydrogenase (an indicator of neuronal cell death) in culture media. Inclusion of 
NS-398, a selective COX-2 inhibitor, significantly attenuated neuronal cell death and the 
corresponding increase in PGE2 concentration triggered by LPS (Araki et aI., 2001). This 
attenuation was less pronounced using enriched neuronal cultures, suggesting an 
important contribution of glial cells. The role for glia in several central and peripheral 
pathologies is currently the subject of intense investigation. Similar results were 
described with 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)-phenyl-2eH)-
furanone (DFU), a selective COX-2 inhibitor (Strauss and Marini, 2002). Pretreatment of 
cultured cerebellar granule neurons with DFU (10 nM) protected almost all vulnerable 
cells from glutamate-induced cell death, and reduced the concomitant increase in PGE2 
by 50%. 
The protective effects afforded by inhibitors of prostaglandin synthesis have also 
been reported in vivo using several different neuropathological models. Subcutaneous 
injection of carrageenan into the plantar surface of the hind paw induces a hyperalgesic 
state that has both central and peripheral components (Dirig et al., 1998). Dirig and 
collegues (1998) showed that intrathecal pretreatment with either a non-selective COX 
inhibitor or a COX-2 selective inhibitor prevented the development of hyperalgesia. In a 
focal cerebral ischemia model, treatment with oral indomethacin (20mglkg) before 
ischemia in the fronto-parietal region of rat brain reduced infarct volume by 43% and the 
concurrent increase in local PGD2 concentration. Further support for a pathophysiological 
contribution ofprostanoids is the observation that COX-2 knockout mice exhibit reduced 
susceptibility to focal cerebral ischemia induced by middle cerebral artery occlusion 
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(Iadecola et aI., 2001). Homozygous knockouts showed the most significant reduction in 
infarct volume (-38%) while reduced protection was noted in hetereozygous knockouts 
(- 20% reduction). In the same study, brain lesion volume induced by NMDA 
microinjected into the cerebral cortex was also reduced in COX-2 -/- mice; an effect 
mimicked by NS-398 (20mglkg i.p.) in COX-2 +/+ mice, but not COX-2 -/- mice. 
The deleterious effects of COX products have also been demonstrated in models 
of ncuropathic pain. Zhao et al. (2000) reported that indomethacin (IOOllg), injected 
intrathecally 2h after unilateral spinal nelVe ligation (L5 and L6), attenuated the 
development of tactile allodynia for up to 4 weeks after nerve injury. Identical treatment 
I day after nerve injury produced a similar effect, but resulted in a lesser degree of 
prevention of allodynia, suggesting a limited window of opportunity for post-injury 
protection. Comparable effects have been reported using knockout animals. Mice 
lacking one of the tenninal prostaglandin synthases, namely membrane-associated POE 
synthase (mPGES-l, the enzyme that converts PGH2 to PGE2), failed to develop 
mechanical allodynia or thennal hyperalgesia following unilateral L5 spinal nerve 
transection (Mabuchi et aI., 2004). Interestingly, these same mice showed nonnal 
thennal and mechanical nociceptive responses. Overall, these studies support the 
hypothesis that prostaglandins, generated by nerve injury, are important mediators of 
several neuropathological states, including neuropathic pain. To date, emphasis has been 
directed at COX-2. The contributions of COX-I and the putative COX-3 isozyme remain 
to be detennined. 
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1.13 ROLE FOR SPINAL NITRIC OXIDE IN NOCICEPTION, HYPERALGESIA 
AND ALLODYNIA 
Using cerebellar slices, Bredt and Snyder (1989) reported that glutamate, acting 
through the NMDA receptor complex, generated NO. This product appeared after an 
increase in intracellular ci+ concentration and the activation of NOS (Schuman and 
Madison, 1994; STenman and Bredt, 1997). Nitric oxide is able to diffuse oul orlhc cells 
from which it is generated and act on neighbouring clements (e.g. neurons and astrocytes) 
as a neurotransmitter. In this manner, NO is thought to subserve important 
neuromodulatory functions in the eNS (Snyder, 1992). Because of the high affinity that 
NO has for guanylyl cyclase, most NO-mediated effects arc cGMP·dcpcndcnt, and arc 
therefore upstream from protein kinase G. These effects include the modulation of 
neurotransmitter release, gene expression (including those for COX), learning, memory, 
and prostaglandin synthesis (independent of that related to COX expression) (Wang and 
Robinson, 1997; Bredt and Snyder, 1992; Mollaee et al., 1995; Haley et aI., 1992; 
Garthwaite et aI., 1988). 
Extensive evidence links spinal NO to nociceptive processing. For example. 
incubation of an astroglial cell line with NMOA (10-600 ~M) produced a dose-dependent 
increase in NO. PGE2 and cGMP; effects inhibited by L-NAME (Mollace et al.. 1995). 
The NO donor, sodium nitroprusside, evoked release of CGRP and substance P from 
dorsal hom slices (Garry et al.. 1994). In contrast, L-NAME blocked thermal 
hyperalgesia in the rat tail flick and tail immersion tests (Radhakrishnan et al., 1995) as 
well as PGE2-induced allodynia and hyperalgesia (Minami et aI., 1995b; Park et aI., 
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2000). Dolan and Nolan (1999) reported that i.t. NMDA-induced allodynia in sheep is 
blocked by either L-NAME (2 flmol i.t.) or the COX-2 inhibitor, DFU (200 nmol Lt.). 
The relevance of spinal NO to neuropathic pain is supported by studies demonstrating 
attenuation of mechanical allodynia by Lp. L-NAME in the spinal cord ischemia and 
L51L6 nerve ligation models (Hao and Xu, 1996; Yoon et aI., 1998) Further support is 
drawn from the suppression of the neurochemical and cardiovascular indices of 
strychnine-al1odynia by L-NOARG (Milne et al., 2001). 
In summary, NOS and COX are co-activated by NMDA receptor activation 
secondary to exaggerated glutamate release immediately after nerve injury. Isoforms of 
NOS and COX appear to be up-regulated in the dorsal hom following nerve injury, and 
their inhibition is significantly anti-allodynic in a variety of experimental models. Thus, 
spinal NO and prostaglandins may work in concert to effect central sensitization early 
after nerve injury (see figure 1.1). 
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Figure 1.1 Schematic representation illustrating several dorsal horn systems that 
contribute to the processing of primary afferent input following nerve injury. 
Primary afferent A-fibers release excitatory amino acid (glutamate) products. Some 
postsynaptic elements contain nitric oxide synthase and are able to release NO upon 
a rise in intracellular CaZ+. For glutamate, direct monosynaptic excitation is 
mediated by NMDA and non-NMDA receptors. Excitation in second-order neurons 
via a NMDA receptor leads to an increase in intracellular Ca1+, activation of 
phospholipase A2, NOS, and phosphorylating enzymes. COX products (PG) and 
NO are formed and released. These agents diffuse extracellularly and facilitate 
transmitter release (retrograde transmission) from primary and nonprimary 
afferent terminals by either a direct cellular action or by an interaction with a 
specific class of receptors (e.g., PG type E (EP) receptors for prostanoids). 
(Modified from Yaksh et a!., 1999) 
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1.14 NEUROPATHIC PAIN MODELS 
Animal models are used extensively in basic pain research. This is done on the 
premise that, by serving as surrogates for human pain states, the mechanisms and 
etiologies underlying these states can be detennined and, in turn, that new drugs and 
treatment strategies can be reliably predicted. There are now a number of distinct models 
of neuropathic pain that mimic direct injury to the central or peripheral nervous system, 
metabolically-based neuropathies, and drug-induced pathologies. 
1.14.1 PERIPHERAL NERVE INJURY MODELS 
The three most commonly used models of peripheral nerve-injury are the chronic 
constriction injury (CCI), the partial sciatic nerve ligation (PSL), and the L5/L6 spinal 
nerve ligation (SNL) models. 
1.14.1.1 CHRONIC CONSTRICTION INJURY MODEL 
Chronic constriction injury was the first and probably the most widely-used 
model of neuropathic pain. Four loose chromic gut ligatures arc placed unilaterally 
around the rat sciatic nerve at mid-thigh level eliciting a local inflammatory response 
(Bennett and Xie, 1988). As the nerve swells, it becomes tightly constricted by the 
ligatures leading to thenna! and mechanical hyperalgesia, as well as cold and tactile 
allodynia. These sensory changes are evident within one week after ligation and last 
approximately two months, although the duration can vary (Bennett and Xie, 1988; Attal 
et aI., 1990). Other outcomes included suppression of appetite, and frequent spontaneous 
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nocifensive behaviors. The authors also su ggested that rats subjected to CCI have 
spontaneous pain as evidence by the presence o f mild to moderate autotomy. This model 
has been used extensively to investigate: a) s pinal and supraspinal sensitization after 
injury; b) the genetic basis of neuropathic pain .; and c) pharmacological interventions for 
possible use in human pain states. 
1.14.1.2 PARTIAL SCIATIC NERVE LIGATION MODEL 
Seltzer et al. (1990) described a model of neuropathic pain that attempts to mimic 
partial pcriphcral nerve injury in humans. Inj u ry is induced by the unilateral application 
ofa loose ligature that narrows the sciatic nerve by 113-112 at the high·thigh level. Rats 
exhibit signs of mechanical allodynia and thermal and mechanical hyperalgesia within 
hours of ligation; effects whieh can persist for over seven months. These symptoms 
appear to have a sympathetically-mediated componcnt similar to human causalgia. 
Spontaneous pain also seems to be present as rats sometimes lick the affected paw in the 
absence of stimulation. Autotomy is sometimes present but it is not a consistent feature 
of the model. Evoked pain can also develop a bilateral pattern of response suggesting the 
recruitment of central neuroplastie mechanisms. 
1.14.1.3 LSIL6 SPINAL NERVE LIGATION (SNL) MODEL 
In 1992, Kim and Chung reported another model resembling human causalgia in 
which the L5 and L6 spinal nerves are tightly ligated (unilatcrally) just distal to the dorsal 
root ganglia. Allodynia and hyperalgesia develop within the first 24 h after injury and 
last for at least 4 months. Numerous modifications of SNL have since been reported, 
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including ligation of L5 only, as well as both ligation and transection of L5. These 
variations, while not commonly used and less well-characterized, result in a similar 
pattern of allodynia and hyperalgesia. 
Of the three models, SNL elicits the most pronounced mechanical allodynia and is 
least likely to cause autotomy. This latter feature, along with the lack of spontaneous 
pain after SNL, is a major advantage of this model. The degree of hyperalgesia (thennal 
and mechanical) and bilateral development of NP are comparable among the three 
models. Another noteworthy advantage of SNL is the reproducibility of the injury from 
one animal to another. This is aided by the use of tight as compared to loose or partial 
ligation where consistency is more difficult to ach ieve. 
Ligation of the L51L6 spinal nerves does necessitate more extensive surgery than 
the other models making it somewhat more challenging to use. A related issue is the risk 
of damage to the L4 spinal nerve given its proximity to L5 and the need to separate the 
two before ligation. However, inadvertent injury can be detected by the emergence of 
sign ificant motor deficits in the ipsilateral hindlimb since the L4 root contains an 
abundance of motor fibers (Kim and Chung, 1992). 
1.14.1.4 PERIPHERAL NERVE TRANSECTION 
The use of early models involving complete transection of a peripheral nerve, 
often the sciatic nerve, is generally in decline. These models most closely resemble 
conditions of limb amputation. Following transection, a neuroma fonns at the proximal 
nerve stump consisting of regenerating axonal sprouts. This is thought to be intimately 
involved in the mechanisms underlying the NP that ensues (Fried et al., 1991; Devor et 
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aI., 1976). Complete transection of a peripheral nerve almost always leads to tactile 
allodynia, thermal hyperalgesia, excessive grooming of the denervated limb, and 
autotomy (Wall ct aI., 1979). This latter behavior is now considered to be a reflection of 
NP arising from the nerve lesion and can be used as a behavioral correlate (Kauppila et 
al.,1.998). 
L.L4.L.S SPARED NERVE INJURY MODEL 
Recently, Decosterd and Woolf (2000) described another model mimicking partial 
nerve injury. This involves axotomy and ligation of the tibial and common peroneal 
nerves, while leaving the sural nerve intact. This represents partial denervation of the 
ipsilateral limb, while preserving some sensory input, thus allowing investigation of both 
injured and uninjured fibers. In this model, injured animals exhibit robust mechanical 
and thermal sensitivity in the affected dennatomes within 24h; effects that persist for 
more than 6 months. 
1.14.2 CHEMICAL-OR METABOLICALLY-INDUCED NP MODELS 
Clinical NP can arise from metabolic disorders such as diabetic neuropathy, or 
treatment with anti-neoplastic drugs and immunotherapy. Diabetic neuropathy can be 
induced in experimental animals by a single injection of streptozocin (e.g. 75mglkg i.p.) 
which is toxic to beta cells in the pancreas. This treatment also results in ultrastructural 
changes to nerve fibers that may explain, in part, the long-lasting (Le. months) thermal 
and mechanical hyperalgesia, as well as cold and tactile allodynia that develop within 10 
days of treatment (Collrteix et a1., 1993). 
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There are several models of chemotherapy-induced NP, including treatment with 
vincristine, cisplatin, or taxoL Each can cause dose- and treatment timc-dcpendent 
pcripheral neuropathies which often become the limiting factor in their clinical use 
(Strumberg et aI., 2002; Aley et aI., 1996; Cavaletti et aI., 1995). In animals, treatment 
with the respective agent is required for several days resulting in treatment-dependent 
forms of hyperalgesia and/or allodynia. Thc cxact mechanisms contributing to the 
resulting NP are unknown, but severe demyelination and axonal degeneration are known 
to occur. 
Pediatric neuroblastomas are oftcn treatcd with a chimeric human/mousc anti-
GD2 (GD2 - a glycosphingolipid) antibody which can result in severe pain. Infusion of a 
monocolonal anti-ganglioside antibody (i.v. or i.t.) in experimental animals leads to 
quantifiable mechanical allodynia, but no thermal hyperalgesia (Slaft et aI., 1997; Sorkin 
et aI., 2002). The exact mechanisms leading to these sensory changes are unknown. 
Howevcr, the antigen that binds to the antibody is known to bc present on sensory nerves 
and is probably a relevant factor (Slart et aI., 1997). 
1.14.3 CENTRAL NEUROPATHIC PAIN MODELS 
Neuropathic pain is a common problem in paticnts with spinal cord injury (see 
rcview, Yezicrski, 1996). Thcrc arc two common modcls of this central pain state: the 
spinal cord ischcmia- and excitotoxic lesioning-models. 
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1.14.3.1 SPINAL CORD ISCHEMIC INJURY MODEL 
Focal spinal cord ischemia can be induced using laser irradiation of the exposed 
spinal cord following the i.v. injection of a photosensitizing dye. The irradiated dye 
causes blood vessel occlusion in a highly restricted and circumscribed area leading to 
subsequent spinal cord injury (Watson et al., 1986; Prado ct al., 1987; Hao cl al., 1991). 
The resulting effects arc mechanical and cold allodynia, hyperalgesia, and autotomy (Hao 
et ai., 1991; Xu et ai., 1992; Hao et al., 1992). The most common explanation for these 
sensory changes is based on the observation that small, inhibitory intemeurons within the 
spinal cord are extremely sensitive to ischemic insult. As a result, their ability to 
modulate afferent sensory input is significantly impaired leading to its miscoding as pain. 
This hypothesis is strengthened by the fact that robust allodynia can be induced by 
pharmacological blockade of spinal GABA" or glycine receptors in otherwise normal 
(uninjured) animals (Yaksh, 1989). 
1.14.3.2 EXCITOTOXIC SPINAL CORD INJURY MODEL 
Local injection of a glutamate receptor agonist into the spinal cord induces 
excitotoxicity and the formation of a focal lesion. Normally, the AMPA reccptor agonist, 
quisqualic acid is used. This is injcctedjust above the lumbar segments, into areas of the 
spinal cord that control sensory function of hindlimb dermatomes. Long-lasting tactile 
allodynia and thermal hyperalgesia result in the dermatomes innervated by the spinal 
segments affected by the drug (Yezierski et al., 1998; Yezierski et al., 1993). Like the 
spinal cord ischemia model, the local injection of excitotoxic amino acids is thought to 
induce the relatively selective loss of inhibitory intcmeurons, thereby disrupting the 
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normal modulation of afferent sensory input. However, other theories have also been 
proposed (Yezierski et aI., 1998) and it is likely that no single mechanism is totally 
responsible. 
1.15 HYPOTHESIS AND SPECIFIC OBJECTIVES 
Increased glutamatergic tone, acting through spinal NMDA receptors, leads to 
synthesis of spinal prostaglandins and NO; obligatory events preceding the facilitation of 
high-threshold (C-fiber) input and the development of hyperalgesia. Sustained C-fiber 
activity is also known to trigger rapid induction of COX-2 and iNOS in the spinal cord 
which could exacerbate this central sensitization process by catalyzing further prostanoid 
and NO synthesis. Because these changes are initiated by and thus dependent upon 
central NMDA-receptor activation, they arc normally only recruited by sustained C-fibre 
(nociceptive) input. 
One of the defining and clinically important features of neuropathic pain is 
allodynia. Allodynia is known to be triggered by input from low-threshold primary 
afferent (An) fibers not normally involved in pain. While the mechanisms underlying 
this debilitating condition are poorly understood, there is growing evidence that spinal 
prostaglandins, generated in the spinal cord after nerve injury, may play an integral role 
in the early pathogenesis of allodynia. There is additional evidence that NO, generated in 
the spinal cord after nerve injury (i.e. secondary to spinal NMDA-receptor activation), 
works in concert with prostaglandins to alter sensory processing, thereby leading to the 
miscoding of low-threshold input as pain. 
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The purpose of this research was to test the hypothesis that nerve injury triggers 
the synthesis of prostaglandins in the spinal segment(s) affected by that injury and that 
this early neurochemical response to nerve injury is a critical step in the development of 
long-term (prostaglandin-independent) allodynia. Increases in the cellular machinery 
required for spinal prostaglandin synthesis has already been reported after spinal nerve 
ligation (Zhao et aI., 2000), along with increases in prostaglandin receptors (Ma and 
Eisenach, 2002). Interestingly, these changes were temporarily correlated with nerve 
injury, but were transient. Thus, it is possible that the role for spinal prostaglandins in 
neuropathic pain changes with time and this lead us to investigate the importance of these 
neuromodulators in a similar time frame that others have reported related changes. 
It is further hypothesized that spinal NO interacts with prostaglandins to effect 
tactile allodynia early after nerve injury. This interaction has been suggested several 
times in the literature (e.g. Dolan and Nolan, 1999; Park et al. , 2000), but has yet to be 
pharmacologically characterized by isobolographic analysis. Defining the nature of this 
interaction, whether it is synergistic, additive, or antagonistic could have a significant 
impact on the management of neuropathic pain. Characterization is necessary if 
simultaneous inhibition of COX and NOS is going to be considered, both of whose 
enzymatic products have been shown to be pro-allodynia (see sections 1.10, 1.11, 1.13). 
These hypotheses were tested using the L51L6 spinal nerve ligation model of 
neuropathic pain - a commonly used and well-characterized model of hyperalgesia and 
allodynia. Spinal nerve ligation elicits a pronounced mechanical allodynia, particularly 
in pre-pubescent rats, while being least likely to cause autotomy. This lack of autotomy 
as well as an apparent absence of spontaneous pain, are major advantages of this modeL 
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Another significant advantage of the spinal nerve ligation model is the consistency of 
aUodynia among animals. This is mostly due to the model's surgical endpoint - tight 
ligation of the spinal roots as opposcd to to loose ligatures or partial nerve ligation, where 
consistency is more difficult to achieve. This consistency, as well as absence of 
spontaneous recovery from allodynia, provided an excellent animal model to use in this 
study. Accordingly, the following specific objectives were undertaken: 
To determine if brushing the allodynic dermatome of nerve injured rats evokes the 
release of PGE2 into lumbar CSF, and whether this effect is dependent on spinal 
COX activity. 
2. To determine the time-course of prostaglandin-dependent allodynia following 
nerve injury, and its sensitivity to i.t. COX inhibitors or EP receptor antagonists. 
3. To determine the COX isoforms responsible for prostaglandin synthesis in the 
prostaglandin-dependent phase of allodynia. 
4. To determine if i.t. COX inhibitors, given hours after spinal nerve ligation, 
prevent the establishment of long term allodynia, and to identify the relevant 
COX isoform(s). 
5. To determine the nature of the pharmacological interaction bctween spinal 
prostaglandins and NO in nerve-ligated (allodynic) animals. 
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2.0 SPINAL NERVE INJURY ACTIVATES PROSTAGLANDIN SYNTHESIS 
IN THE SPINAL CORD THAT CONTRIBUTES TO EARLY 
MAINTENANCE OF TACTILE ALLODYNIA 
Michael P. Hefferan, Pamela Carter, Melissa Haley and Christopher W. Loomis, Pain 
2003; IOU39-147. 
2.1 INTRODUCTION 
An intriguing and clinically important manifestation of neuropathic pain is 
allodynia. This is an abnonnal condition in which innocuous stimuli (i.e. light touch) 
acquire the ability to evoke severe pain. Allodynia is known to be triggered by input 
from low-threshold primary afferent (AB) fibers that are not nonnally involved in pain 
(Campbell et a\., 1988; Price et aI., \989). However, the mechanisms underlying this 
change in sensory processing are poorly understood. 
Prostaglandins, synthesized in the spinal cord in response to noxious (C-fibcr) 
input, are known to facilitate nociceptive transmission (see McCormack 1994a,b for 
review). Thus, i.t. ketorolac (non-selective COX inhibitor) inhibited the second phase of 
the rat formalin test (Yaksh and Malmberg, 1993), and the spinal release of substance P 
and calcitonin gene-related peptide in a peripheral inflammatory model (Southall el al., 
1998). Similarly, i.t. S(+)-ibuprofen, but not the R(-) isomer, reduced the concentration 
of PGE2-Li in rat spinal CSF following subcutaneous (s.c.) formalin (Malmberg and 
Yaksh, 1995). Consistent with these reports are studies confirming the presence of cyclo-
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oxygenase (COX) and prostaglandin receptors in the outer laminae of the spinal dorsal 
hom (Beiche et aI., 1996; Willingale et a l. , 1997; Vane et aI., 1998). 
The observation that prostaglandins exert a central nociceptive action 
independent of their peripheral inflammatory and algesic effects raises questions about 
their contribution in abnormal (neuropathic) pain states. Indeed, there is growing 
evidence that spinal prostaglandins playa role in neuropathic pain. For example, i.1. 
ketorolac reduced thermal hyperalgesia and cold allodynia in the chronic constriction 
injury model (Parris et al. , 1996). lntrathecal ibuprofen attenuated, in a stereospecific 
manner, the cardiovascular, behavioural and neurochemical indices of tactile allodynia in 
the i.t. strychnine model (Hall et aI., 1999). Focal application of COX inhibitors to the 
dorsal surface of the rat spinal cord also produced a highly localized anti-allodynic effect 
in the spinal bicuculline model (Zhang et aI., 200 1). That spinal prostaglandins may be 
important in neuropathic pain is further supported by reports that COX-2 protein is up-
regulated as early as one day after spinal nerve ligation (Zhao et al., 2000), and that the 
acute i.t. injection of PGE2 induces hyperalgesia and allodynia in experimental animals 
(Uda et al., 1990; Z. Zhang, M.P. Hefferan and C. W. Loomis, unpublished results). 
Preliminary work by Zhao et al. (2000) showed that indomethacin, given i.t. one 
day after spinal nerve ligation, partially inhibited the development of allodynia in the rat. 
However, the relationship between tactile stimulation and release of spinal prostaglandins 
in allodynic animals, the pharmacology of prostanoid modulation, and the effect of 
prostaglandins inhibition on established allodynia in the first two weeks of spinal nerve 
injury have not been reported. The present study provides the first report of brush-
evoked cbanges in PGE2 concentration in spinal CSF of allodynic rats using the spinal 
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nerve ligation model (Kim and Chung, 1992), and the anti-allodynic cffects of sterco-
specific, isofonn-selective, and non-selective COX inhibitors, and a prostaglandin (EP) 
receptor antagonist, given Lt. 2-12 days after ligation. 
2.2 METHODS 
All studies were conducted in accordance with the guidelines of the Institutional 
Animal Care Committee of Memorial University of Newfoundland, St. John's, NF, 
Canada. 
Animals: Male Sprague-Dawley rats (weights indicated below) were obtained 
from the Vivarium, Memorial University of Newfoundland and were housed in standard 
cages with woodchip bedding. Animals had free access to food and water and were 
housed singly following surgery. A 12112 h light cycle (lights on at 0700 h) was used 
throughout. 
Intrathecal catheterization: Intrathecal catheters were implanted in rats 
weighing 100-130 g as previously described (Shennan and Loomis, 1994). A 6.S-cm 
catheter was used for tennination near the lumbar enlargement in these smaller animals 
(dead volume 6 ilL). The catheter was sterilized with 70% alcohol and filled with sterile 
saline. Under halothane anesthesia, the catheter was inserted through an incision in the 
atlanto-occipital membrane of the cisterna magna. The catheter was externalized behind 
the head and scaled with a piece of stainless steel wire. Rats exhibiting normal gait, 
feeding and grooming behaviour were housed separately and allowed to recover for at 
least three, and not more than four days. Some animals were implanted with chronic i.t. 
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microdialysis catheters, or intravenous (Lv.) catheters (PE-50) in the right external 
jugular vein for i.v. injections. Microdialysis catheters (Ld. 240 )lm, o.d. 290 11m, MW 
cutoff - 10 kDa) were constructed from triple lumen PE-5 tubing (Spectranetics, 
Colorado Springs, CO, USA) using a modified method of Marsala et al. (1995). Each 
animal was implanted with a new microdialysis catheter; no catheters were reused. 
Dialysate conccntrations were equal to 31.7 ± 2.7% of the external PGE2 concentration at 
a flow rate of 10 IlVml in vitro. This value is similar to that reported by Malmberg and 
Yaksh (1995). 
Spinal Nerve Ligation: Following recovery, neuropathy was induced using the 
method of Kim and Chung (1992), as modified by Chaplan et al. (1994). Rats were 
anesthetized with halothane and a dorsal midline incision made from L3-S2. Using blunt 
dissection, the left posterior interarticular process was located and resected to aid 
visualization of the L6 transverse process. This was partially removed to expose the L4 
and L5 spinal nerves. Once separated, the L5 spinal root was tightly ligated with 6-0 silk 
thread. The L6 spinal root was then located medial and caudal to the sacroiliac junction 
and ligated in the same manner. The wound was closed with 4-0 silk sutures in two 
layers, cleaned with 70% alcohol and a 5-ml bolus of lactated Ringer's solution was 
injected intraperitoneally. The animal was placcd under a wamling light during recovery 
from anesthesia, and returned to the animal care facility for three days before 
experimentation. Sham surgery was performed identical to above, except each spinal 
nerve was identified, isolated in a similar fashion but not ligated. 
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Microdialysis: Intrathecal microdialysis (Marsala et aI., \995) was conducted I 
day before and 5 days after spinal nerve ligation in conscious animals. Briefly, the 
inflow channel of the microdialysis catheter was connected to a microsyringe pump. 
Artificial CSF, sterilized by filtration through a 0.22 11m pore filter (Micron Separations 
Inc., Edmonton, Canada) was perfused at a rate of 10 Ill/min. Th is flow rate, selected on 
the basis of previous work (Malmberg and Yaksh, 1995), produced an in vitro recovery 
rate of31.7±2.7% of the ex.ternal PGE2 concentration and has been established to balance 
adequate sample size, sampling time, and recovery rate (see chapters 2 and 3; also 
Malmberg and Yaksh, 1995; Marsala et aI., 1995; Hefferan et al. 2003a,b). After a 30-
min washout period, a baseline sample (100 Ill) was collected (no paw sti mulation). The 
plantar surface of the affected hind paw was then lightly brushed with a cotton-tipped 
applicator. This was repeated for 2 min followed by a 1 min rest over 10 min (6 min of 
stimulation in 10 min). The samples were collected on ice and immediately frozen at -
80·C until assayed. The concentration of PGE2 was determined using a commercially 
availab le ELISA kit (product II 514010, Cayman Chemical, Ann Arbor, M1). 
Testing: Mechanical allodynia was quantified by determining the 50% paw 
withdrawal threshold using von Frey filaments (Chaplan et aI., 1994). Briefly, rats were 
placed in a plastic cage with a wire-mesh bottom to allow access to the plantar surface of 
the left hind paw. Following a 20-min acclimatization period, a control threshold was 
measured. Drug or vehicle was then injected i.t. and thresholds were determined every 
20 min for up to 3 h. Ex.periments were carried out during the daylight portion of the 
circadian cycle (0800-1800 h). All drug testing occurred 2- 12 days after nerve ligation. 
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Drugs were administered on alternate days with the investigators (pC, MH, MPH) 
blinded to the drug treatment. No animal received more than 6 drug injections in total. 
For all experiments, allodynia was defined as a withdrawal threshold of <4 g. Animals 
with values ;::4 g were excluded (Chaplan et aI., 1994). 
Drugs: Due to their highly lipophilic nature, all drugs were dissolved in 100% 
DMSO and diluted with the same. They were injected i.t. using a Hamilton syringe and a 
hand-operated microsyringe pump. All equipment was sterilized with 70% alcohol 
before injection and thoroughly rinsed with 0.9% sterile saline. Drugs were injected i.t. 
in conscious, unrestrained rats in a volume of 5 III followed by 8 III of stcrilc saline. The 
i.t. catheter was immediately resealed with the stainless steel plug. S(+)-ibuprofen 
(active stereo-isomer) and R(-)-ibuprofen, (inactive isomer) were purchased from 
Research Biochemicals lnt. (Natick, MA, USA); SC-51322 (an EP receptor antagonist 
with modest selectivity for the EP I subtype) was purchased from Biomol (Plymouth 
Meeting, PA, USA); SC-236, (a selective COX-2 inhibitor) and SC-560 (a selective 
COX-I inhibitor) were generous gifts from Searle (Skokie, IL, USA). The selectivity 
ratio, defined as the ICso COX-IIICso COX-2, for SC-236 is 1780, while that of SC-560, 
defined as ICso COX-2IICso COX-I, is 10700. These data were detennined using human 
COX-l and COX-2 and provided by Searle (Skokie, IL, USA). 
Data Analysis: Results are presented as either raw withdrawal thresholds (g) or 
nonnalized as % anti-allodynia. The latter was calculated as follows: % anti-allodynia '" 
(test value - control value)/(15 - control value) x 100 (Chaplan et al., 1997). In our 
experiments, 15 g was the approximate withdrawal threshold in naive rats and was 
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therefore selected as the threshold representing complete reversal of allodynia (i.e. 100% 
anti·allodynia); this is consistent with previous reports (Chaplan et aI., 1994). All dose· 
response curves were calculated using the peak effect of each dose taken from the time· 
course data. PGE2 concentrations are presented as percent of baseline (defined as release 
in the absence of brushing). Absolute PGE2 concentrations in pg/ml arc also reported. 
All statistical testing was performed using Sigmastat'll 2.03 for Windows'll. Multiple 
comparisons were done using one·way analysis of variance followed by Student 
Newman·Keuls test. All results are shown as mean ± SEM. P < 0.05 was considered to 
be statistically significant. 
2.3 RESULTS 
Tight ligation of the L51L6 spinal nerves produced mechanical allodynia 
manifested as protection of the affected hind paw ipsilateral to the nerve ligation (Fig. 
2.1 alb) and a significant reduction in the paw withdrawal threshold (Fig. 2.2). 
Thus, animals often kept the affected hind paw elevated above the cage floor 
and/or in a 'cupped' position presumably to prevent the mid·plantar surface from 
touching the cage. Apart from this abnormality, rats were healthy, exhibited normal 
grooming and fceding behavior, and regular weight gain. Withdrawal thresholds 
decreased from pre·surgical values of :<!::15 g to 1·3 g after ligation. In a control group, 
this reduction was evident as early as I day post·ligation and remained stable for up to 18 
days. Mechanical allodynia (defined as a withdrawal threshold :-::;4 g) was observed in 
greater than 90% of ligated rats (55 of60). 
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Figure 2.1. Tight ligation of the left L51L6 spinal nerves results in tactile 
allodynia in the ipsilateral hind paw. This effect is observed as cupping of the 
affected paw (A), as compared to that of a sham-operated rat (B). 
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Figure 2.2 Tight ligation of the Jefl lumbar 5/6 spinal nerves produced tactile 
allodynia in the plantar surface of the affected hind paw. Left-paw 50% withdrawal 
thresholds were determined over 18 days following spinal nerve ligation or sham-
surgery (day 0). Each point represents the mean ± SEM of 6-8 experiments. All 
thresholds are significantly different from pre-ligation thresholds in ligated animals 
(p~0.017). 
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The withdrawal threshold in all sham-operated rats remained unchanged from pre-
surgical values (fig. 2.2). The mean withdrawal thresholds after nerve ligation but before 
drug treatment were not statistically different across experimental days (data not shown). 
Mechanical allodynia was accompanied by an increase in the evoked release of 
PGE2 into spinal CSF. Figure 2.3 illustrates the concentration of PGE2 in microdialysate 
samples collected from the i.t. space of ligated and sham-operated rats, 1 day before and 
5 days after surgery. Brushing the affected hind paw evoked a significant increase (199 ± 
34% of baseline; p=0.042) in allodynic rats as compared to sham-operated controls (92 ± 
7%). Pretreatment with Lt. S(+)-ibuprofen (100 I-1g), but not i.t. R(-)-ibuprofen (100 I-1g), 
60 min before brushing, decreased brush-evoked PGE1 release to 142 ± 15% of baseline 
(fig. 2.3). This was not significantly different from baseline. Brushing the contralateral 
paw in ligated rats, or brushing either paw before surgery had no detectable effect on 
PGE1 release in either group (fig. 2.3). There were no differences in the basal release of 
PGE2 I day before or 5 days after surgery in either ligated or sham-operated rats. The 
absolute concentrations of PGEl in spinal dialysate samples were as follows: Pre-ligation: 
776 ± 235 pg/ml (no brushing) and 752 ± 180 pg/ml (brushing); Post-ligation: 672 ± 162 
pg/ml (no brushing); 1337 ± 454 pg/ml (brushing). 
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Figure 2.3. Brushing of the allodynic paw evoked spinal PGEz release. Vertical 
bars represent the concentration of PGEl in spinal dialysate samples collected in 
conscious, unrestrained rats, 1 day before and 5 days after either spinal nerve 
ligation or sham·surgery. Brushing the plantar surface of the affected hind paw 
after ligation evoked a significant increase in IPGE2!dll ly,"te (*p=0.040; n = 6-7 
animals) compared to sham controls. Brushing before surgery was without effect. 
Intrathecal S(+)-ibuprofen (100 J.lg) administered ~O min before brushing 
significantly reduced the evoked PGEl release in ligated animals. ** Indicates a 
significant difference from the S(+)·ibuprofen-pretreated group (p=O.OII). 
Numbers in brackets above the bars represent the mean ± SEM of 6-7 animals for 
the paw withdrawal threshold in the respective groups. 
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The i.t. injection of 10, 30, 60, or 100 ).1g of S(+)-ibuprofen significantly inhibited 
allodynia. Figure 2.4A shows the time-course of paw withdrawal threshold following the 
i.1. injection of 10 and 100 ).1g of S(+)-ibuprofen. The onset of effect was delayed, 
peaking between 60 and 100 min after injection (fig. 2.4A). A similar time course was 
observed with 30 and 60 ).1g of S(+)-ibuprofen (data not shown). The peak effect and 
duration of action were positively correlated with the i.t. dose. Dose-response analysis 
using the peak effect of each dose yielded a linear relationship over the range of 10-100 
).1g (fig. 2.4B). A similar obscrvation was made using area-under-the-curvc analysis (data 
not shown). In contrast, i.t. R(-)-ibuprofen (60 ).1g), DMSO, or normal saline had no 
effect on paw withdrawal threshold in ligated rats (fig. 2.S). The i.v. or i.p. injection of 
l00).1g of S(+)-ibuprofen was also without effect, as was i.t. delivery at the mid-cervical 
level. No adverse effect on motor function was noted. 
The i.t. injection of SC-S1322 produced a temporary blockade of mechanical 
allodynia (fig. 2.6A). As with S(+)-ibuprofen, the onset was delayed, and peaked at 
between 40 and 60 min. The maximum increase in withdrawal threshold was dose-
dependent as indicated by the linear dose-response curve between 10 and 100 ).1g (fig. 
2.6B). Dose-response analysis using the duration of action ofSC-S1322 yielded a similar 
result (nol shown). Intrathecal SC-S1322 did not appear to affect general motor activity. 
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Figure 2.4. Intrathecal S(+)-ibuprofen significantly reversed allodynia in a dose-
dependent manner. Time-course (A) and dose-response curve (B) for intrathecal 
S(+)-ibuprofen. Each point represents the mean :l: SEM of 6-8 animals. Drug-
induced changes in affected hind paw withdrawal thresholds are expressed as % 
anti-allodynia (see Methods). Dashed lines indicate the 95% confidence intervals. 
In panel A, each asterisk indicates a significant difference from control (time 0; 
p=O.OI7 for lO/-lg group ; p<O.OOl for 100 f.1g group). 
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the mean ± SEM of 3-4 animals. No point is significantly different from time O. (ibu 
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Figure 2.6. Intrathecal injection of the prostaglandin (EP) receptor antagonist, SC-
51322 reversed allodynia. Time-course (A) and dose-response curve (B) for 
intrathecal SC-51322. Each point represents the mean ± SEM of 6-8 animals. 
Drug-induced changes in paw withdrawal thresholds are expressed as % anli-
alJodynia (see Methods). Dashed lines indicate the 95% confidence intervals. In 
panel A. each asterisk indicates a significant difference from control (time 0; 
p<O.OOI for both 10 /-lg and 100 JIg groups). 
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Figure 2.7. SC-236. a COX-2 selective inhibitor, significantly reversed allodynia. 
Time-course (A) and dose-response curve (B) for intrathecal SC-236. Each point 
represents the mean ± SEM of 6-11 animals. Drug-induced changes in the affected 
hind paw withdrawal thresholds are expressed as % anti-allodynia (see Methods). 
Dashed lines indicate the 95% confidence intervals. In panel A. each asterisk 
indicates a significant difference from control (time 0; p=O.SIO for 10 JIg group; 
p<O.OOI for 100 Ilg group). 
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To investigate whether the prostaglandins implicated in this model are 
synthesized by spinal COX-2 and/or COX-I, the effects of Lt. SC-236 and SC-560 were 
determined. SC-236 significantly inhibited mechanical allodynia (fig. 2.7A) in a dose-
dependent manner (fig. 2.7B). The maximum increase in paw withdrawal threshold, 
corresponding to 57.3 ± 3.7 % anti-allodynia, was achieved with the 100 }1g dose. In 
contrast, SC-560 (up to 1000 }1g) yielded only a modest increase in withdrawal threshold 
(fig. 2.8A). Although, this effect was dose-dependent (fig. 2.8B), the dose-response 
curve was considerably more shallow (slope = 0.19 ± 0.05%) as compared to SC-236 
(slope = 0.51 ± 0.07%) (P = 0.006). Neither SC-236 nor SC-560 elicited any obvious 
adverse effects on motor function, even up to 1000 Ilg ofSC-560. 
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Figure 2.8. The COX-) selective inhibitor SC-560 had minimal effect on allodynia. 
Time-course (A) and corresponding dose-response curve (B) for intrathecal SC-560. 
Data are shown as the mean ± SEM with each data point representing 6-8 animals. 
Drug-induced changes in left-paw withdrawal thresholds are expressed as % anti-
allodynia (see methods). Dashed lines indicate the 95% confidence intervals. In 
panel A. each asterisk indicates a significant difference from control (time 0; 
p=0.546 for 10 ~g group; p<0.001). 
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2.4 DISCUSSION 
Tight ligation of the left L5 and L6 spinal nerves produced robust tactile allodynia 
in the plantar surface of the left-hind paw. This was evident from the marked reduction 
in withdrawal threshold 24 h after ligation; an effect that remained stable for at least 18 
days. These observations arc consistent with previous studies using the spinal nerve 
ligation model (Kim and Chung, 1992; Chaplan et al., 1994). The magnitude, stability 
and duration of the change in sensory threshold, and the absence of spontaneous recovery 
from allodynia, provided the requisite conditions for subsequent spinal dialysis and dosc-
response studies. 
Spinal CSF concentrations of PGE2 were detennined before and after surgery, 
under basal (no brushing) and evoked (brushing) conditions. Brushing the plantar surface 
of the left hind paw enhanced PGE2 release in allodynic, but not sham-operated animals. 
This effect was attenuated by i.t. pretreatment with the active isomer of ibuprofen, 
confinning its dependence on spinal COX activity. In contrast, basal release was 
unchanged from pre-surgical values in both the ligated- and sham (conlrol)-groups. 
These data suggest that spinal prostaglandin release can increased by brushing the 
affected dennatome - likely triggered by primal)' afferent activity from that dermatome. 
This conclusion is supported by the absence of PGE2 release when the contralateral 
dermatome was brus~ed, and an apparent temporal relationship between brushing, PGE2 
release and allodynie responses. The lack of changc in basal PGE2 concentration is also 
consistent with the absence of spontaneous pain behavior in this experimental model 
(Kim and Chung, 1992). Since prostaglandins are synthesized de novo following cell 
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activation (they arc not stored; Rang et aI., 1999), these results also suggest that spinal 
nerve ligation does not effect a tonic increase in prostanoid synthesis (as detected by 
changes in basal release). Rather, nerve ligation induces further cellular machinery 
required for prostaglandin synthesis in the spinal cord (Zhao et ai, 2000), and thus 
increases its capacity to generate prostaglandins in response to low threshold sensory 
input from the affected dermatomes. Recent work by McCrory and Fitzgerald (2004) 
further supports a nerve injury-driven change in spinal prostaglandin systems. They 
report that human thorocotomy, a condition known to cause injury to intercostal nerves, 
results in an increase in CSF 6-keto-PGF 1u concentration; an effect that can be reduced 
by COX-2 selective or non-selective COX inhibitors. 
Sustained C-fiber input induced by peripheral inflammation is known to trigger 
the synthesis of PGE2 in rat spinal cord; an effect mediated by neuropeptides and 
glutamate released from the central terminals of nociceptive C-fibers (Yaksh et aI., 1999). 
The finding that mild brushing elicits spinal prostaglandin synthesis in allodynic, but not 
control rats, indicates that low threshold input from the affected dermatome is able to 
recruit a central neurochemical mechanism (COX/prostaglandin) normally restricted to 
nociceptive input. Indeed, spinal PGE2 is known to have pro-nociceptive effects 
including: a) the opening of voltage-sensitive Ca2+ channels; b) the enhanced release of 
neuropeptides from primary afferent terminals; and c) the possible modulation of gene 
transcription in sensitized primary afferent fibers (Hingtgen and Vasko, 1994; Millan, 
1999). To determine if prostaglandins, synthesized in the spinal cord of nerve-injured 
rats, are relevant to the emergence ofmcchanical allodynia, pharmacological experiments 
were performed using COX inhibitors and a prostaglandin receptor antagonist. 
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In the present study, R(-)-ibuprofen was used as a control for the active S(+) 
enantiomer (Smith et aI., 1994). Although R(-)-ibuprofen is known to interfere with 
NFKB (Scheuren et aI., 1998), a regulator ofCOX-2 gene expression, it had no effect on 
paw withdrawal threshold, or basal and brush-evoked release of PGE2 in this study. In 
contrast, S(+)-ibuprofen (10-100 ~g i.l.) produced a dose-dependent reversal ofallodynia 
for up to 2 h. This stereo-specific effect strongly suggests that the attenuation of 
allodynia is due to COX inhibition and thus a decrease in spinal prostaglandin synthesis. 
Indeed, S(+)-ibuprofen, but not the R(-) enantiomer, has been shown to: a) lower PGEr 
L1 in CSF dialysate samples following formalin-paw injection (Malmberg and Yaksh, 
1995); b) inhibit the autonomic, motor, and neurochemical responses in the i.t. strychnine 
model of allodynia (Hall et al., 1999); and c) to block the hair deflection-evoked increase 
in PGE2-LI in spinal CSF during strychnine-allodynia (Milne et aI., 2001). In addition, 
focal application of COX inhibitors to the dorsal surface of the spinal cord produces 
significant and highly localized inhibition ofbicuculline-allodynia in the rat (Zhang et al., 
2001). Although others have reported Lt. COX inhibitors to be ineffective in reversing 
established allodynia in the spinal nerve ligation model (Lashbrook et aI., 1999; Zhao et 
aI., 2000), these inhibitors were administered 14 or more days after nerve injury. We also 
have tested i.t. COX inhibitors more than 14 days after ligation, and see little or no anti-
allodynic effect (unpublished observation). In light of this temporal change, retrospective 
data analysis suggests that there is a difference in the anti-allodynie effeet of S(+)-
ibuprofen if the time-course data (2-12 days) are subdivided into 2-7 and 8- 12 day 
periods. In this case, 1 00 ~g Lt. produced approximately 80% anti-allodynia in the early 
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period, whereas during the 8-12 day period, maximal anti-allodynia was approximately 
35%. Unfortunately, an insufficient number of animals were used on each experimental 
day to pennit a more detailed day-to-dayanalysis of the change in anti-allodynic efficacy. 
Regardless, to the best of our knowledge, the present study is the first to demonstrate that 
phannacologieal disruption of spin al prostaglandin signalling early after spinal nerve 
ligation, using either COX inhibitc rs or a prostaglandin receptor antagonist, reverses 
established allodynia for up to 120 ruin after injection. 
Systemic (i.v. or i.p.) adm inistration of S(+)-ibuprofen, at doses that were 
effective when administered i.I., h;ad no effect on paw withdrawal threshold. These 
results strongly suggest that the site of action of S(+)-ibuprofen in reversing tactile 
allodynia is within the central nervous system, and that the effect is unrelated to any 
peripheral actions arising from systemic redistribution. The spinal segments affected by 
nerve ligation, and thus the sites me st likely to exhibit brush-evoked prostanoid activity, 
are in the caudal spinal cord. In this study, the tip of the i.t. catheter was positioned 
adjacent to the L5-L6 spinal segm ents to achieve maximal drug concentration in the 
affected region. When S(+)-ibuprofen was delivered to the mid-cervical region, there 
was no effect on wi thdrawal threshold. The bulk flow of CSF within the spinal 
subarachnoid space moves rostrall y thereby carrying i.t. drugs away from the relevant 
sites of action in this model. Although i.t. drugs can also undergo redistribution through 
the vascular system (i.e. absorpti.on into the spinal microvasculature and subsequent 
movement into the systemic circulation), direct i.v. injection of the maximum i.t. dose of 
ibuprofen was without effect. Tilese data, and that of a previous paper (Zhang et ai, 
2001), support the conclusion that prostanoids exert a highly localized allodynic effect 
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within the affected spinal segments. They also indicate that the delayed onset of action of 
i.1. ibuprofen was not due to migration to rostral sites of action within the CNS. 
Delays in the onset of action of i.t. drugs are not uncommon (Lee and Yaksh, 
1995; Hwang and Yaksh, 1997) and, in the present study, probably reflect the time to 
achieve adequate COX inhibition before behavioral effects were detected. This is further 
supported by the more rapid onset of action of the prostaglandin receptor antagonist, SC-
51322. The significant, dose-dependent inhibition of allodynia by SC-51322 is consistent 
with reports that: a) EP receptors are densely localized in the spinal dorsal hom of the rat 
(Beiche et aI., 1998); b) the EP! receptor antagonist, ONO-NT -012, blocked the allodynia 
evoked by i.1. PGE2 in mice (Minami et aI., 1994, 1995); and c) PGEz , a major 
prostanoid in spinal nociceptive transmission (Malmberg et aL, 1994), has greatest 
affinity for EP receptors (Coleman et al., 1994). 
A role for spinal prostaglandins in allodynia is also supported by reports that i.1. 
PGD2, PGEz or PGFz(t produce hyperalgesia and/or allodynia in conscious mice (Uda et 
al., 1990; Minami et aL, 1992, 1994), the effect of i.t. PGE2 is attenuated in EP] receptor 
knock-out mice (Minami et aL, 2001), and that spinally administered COX inhibitors 
reduce thennal hyperalgesia and cold allodynia in the chronic constriction injury model 
(Parris et al.. 1996) and mechanical allodynia in the strychnine- and bicuculline models 
(Hall et ai., 1999; Zhang et al., 2001). In the present study, i.t. SC-236 and S(+)-
ibuprofen have comparable effects at the highest doses tested (maximum inhibition of 
57.3 ± 3.7% and 69.1 ± 7.9%, respectively). In contrast, the maximum inhibition 
achieved with SC-560, using near equimolar doses and the same post-ligation interval, 
was approximately 20.4 ± 5.5%. These data indicate that COX-2 is the predominant 
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isoform responsible for the de novo synthesis of spinal prostaglandins. This is supported 
by reports of COX-2 mRNA and protein in spinal laminae known to be important in 
nociceptive processing (Beiche et aI., 1996; Willingale et al., 1997; Vane et aI., 1998), 
and the up-regulation of COX-2, but not COX-! protein, as early as one day after spinal 
nerve ligation (Zhao et ai., 2000). Spinal COX-2 is also the major isoform associated 
with thermal hyperalgesia induced by the intraplantar injection of carrageenan in the rat 
(Yamamoto and Nozaki-Taguchi, 1997). 
The mechanism(s) by which spinal prostaglandins contribute to the early 
maintenance of allodynia is unknown. However, studies of their effects on normal 
nociceptive neurotransmission provide some clues. For example, prostaglandins have 
been shown to: a) directly stimulate wide-dynamic range neurons in the rat dorsal hom 
(Baba et aI., 1999); b) sensitize wide-dynamic range neurons in the rat dorsal hom to 
noxious mechanical stimulation of the ankle or knee joint (Willingale et al., 1997); c) 
enhance glutamate and substance P release from primary afferent terminals in the spinal 
cord (Hingtgen et aI., 1995; Ferreira and Lorenzetti, 1996); and d) induce COX-2 activity 
in primary afferents terminals through the EP receptor subclass (Appleton, 1997). That 
these effects might have relevance to the spinal nerve ligation model is supported by the 
observation that the tactile allodynia arising from spinal nerve ligation is highly sensitive 
to spinal NMDA receptor blockade (Lee and Yaksh, 1995). NMDA receptor activation is 
an essential trigger of central prostaglandin synthesis (Dirig and Yaksh, 1999), but is not 
normally involved in low threshold neurotransmission (Urban et aI., 1994). The 
emergence of both NMDA- and prostaglandin-properties in tactile allodynia suggests a 
convergence of cellular events by which low- and high-threshold input are processed. 
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In summary, brushing the dermatomes affected by L5fL6 spinal nerve ligation 
evoked COX-dependent PGEz release from the spinal cord. Treatment with i.t. COX 
inhibitors or an EP receptor antagonist up to 12 days after injury temporarily reversed 
established allodynia. These results support the hypothesis that spinal prostaglandins are 
critical in the early maintenance of allodynia. Based on these data, we propose that that 
a\1odynia induced by L5/L6 ligation in the rat has at least two phases (fig. 2.9); an early 
PG-dependent phase of approximately 10-12 days duration, and a delayed PG-
independent phase that follows. COX-2 appears to be the predominant isofonn, and the 
prostaglandin effects are mediated by spinal EP receptors. The contribution of 
prostaglandin metabolites and/or non-prostanoid neuromodulators. and their interaction 
with spinal prostaglandins, remains to be determined. These results suggest that 
disruption of spinal prostaglandin synthesis and/or their receptor-mediated effects may be 
of benefit in the early managcment ofallodynia, however it is clear from the present data 
that their cfficacy recedes with time, and detailed analysis of exactly when this treatment 
would become ineffective is necessary. 
We are unaware of any controlled clinical studies either confirming or refuting the 
value ofNSAIDS in neuropathic pain. However, our results indicate that the timing of 
NSAID administration is likely to be critical in determining their clinical effectiveness. 
That is, NSAlDS would likely need to be given early after nerve injury to be effective. 
Such an intervention would need to be deliberate given that the symptoms of clinical 
neuropathic pain arc delayed in onset (weeks to months after nerve injury). 
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Figure 2.9. Ti.me course of paw withdrawal thresholds (PWT) following tight 
ligation of the left LS/L6 spinal nerves (day 0). Allodynia is stable for at least 20 
days, and has two phases-an early phase that is PG-dependent and a delayed phase 
that is PG-independent. Data are presented as the mean+/-SEM of 7 animals. 
Shading represents the change in PG-dependence. 
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3.0 INHffilTiON OF SPINAL PROSTAGLANDIN SYNTHESIS EARLY 
AFTER LSIL6 NERVE LIGATION PREVENTS THE DEVELOPMENT 
OF PROSTAGLANDIN-DEPENDENT AND PROST AGLANDIN-
INDEPENDENT ALLODYNIA IN THE RAT 
Michael P. Hefferan, Darren O'Rielly and Christopher W. Loomis, Anesthesiology 2003; 
99,1180-1188 
3.1 INTRODUCTION 
Prostaglandins are synthesized in the spinal cord in response to repetitive C-fiber 
(noxious) input (Malmberg and Yaksh, 1992; Yaksh and Malmberg, 1993; McCormack, 
1994a,b; Southall ct ai, \998) an effect independent of their role in pain and inflammation 
in the periphery. This finding is consistent with the localization of cyclooxygenase and 
prostaglandin binding sites in spinal laminae known to receive nociceptive afferent input 
(Matsumura et aI., 1995; Goppelt-Struebe and Beiche, 1997; Willingale et al., 1997; 
Vane et ai, 1998), and the ability of Lt. non-steroidal anti-inflammatory drugs to block 
both nociceptive behaviours and the concurrent release of prostaglandins into spinal 
cerebrospinal fluid (Malmberg and Yaksh, 1995). 
The facilitatory effect of spinal prostaglandins on nociceptive transmission (see 
review, Millan, 1999) suggests that prostaglandin synthesis early after nerve injury could 
be important in the development of anodynia; a neuropathic condition in which pain is 
evoked by a stimulus that does not normally evoke pain (e.g. cold breeze or light touch; 
Merskey, 1986). Indeed, studies of the effects of spinal prostaglandins on normal 
nociceptive neurotransmission provide clues as to how this could occur. Prostaglandins 
directly stimulate wide-dynamic range neurons in the rat dorsal hom (Baba et al., 2001), 
68 
sensitize these same neurons to noxious mechanical stimulation (Willingale et ai., 1997), 
enhance glutamate and substance P release from primary afferent tenninals in the spinal 
cord (Ferreira and Lorenzetti, 1996; Hingtgen et ai., 1995), and reduce glycine-mediated 
inhibition in the spinal cord (Ahmadi et al.. 2002). 
Certainly. there is growing experimental evidence linking spinal prostaglandins to 
allodynia. Intrathecal prostaglandin 02 (PG02), prostaglandin E2 (PGE2), and 
prostaglandin F2" (pGF2,,) evoke robust allodynia in conscious mice and rats; an effect 
blocked by prostaglandin receptor antagonists (Ferreira and Lorenzetti, 1996; Uda et ai., 
1990) Minami et aI., 1995; Minami et al.. 1995). Allodynia induced by i.1. strychnine 
Yaksh, 1989) features brush-evoked increases in the concentration of PGE2 in spinal 
dialysate (Milne et ai., 200 I) and attenuation by i.t. cyclooxygenase inhibitors (Hall et aI., 
1999). Bicuculline-induced allodynia is also blocked by cyelooxygenase inhibitors given 
locally to the affected spinal segments (Zhang et ai, 2001). In the spinal nerve ligation 
model (Kim and Chung, 1992), significant up-regulation of the cyc100xygenase-2 protein 
has been reported in the spinal cord as early as one day after ligation (Zhao et aI., 2000), 
and allodynia can be temporarily reversed by an i.t. cyc100xygenase inhibitor or EP 
receptor antagonist (see chapter 2; also Hefferan et al.. 2003a). Experimental allodynia is 
also sensitive to spinal N-methyl O-aspartate (NMOA) receptor blockade (Zhang ct ai, 
2001; Lee and Yaksh, 1995; Khandwala et aI., 1997; Leung et ai., 2001; Bennett et aI., 
2000; Hao et ai., 1996; Minami et ai, 2001). NMDA receptor activation, an essential 
trigger for central prostaglandin synthesis (Oirig and Yaksh, 1999), is not normally 
involved in low threshold ncurotransmission (Urban et aI., 1994). The emergence of both 
NMDA- and prostaglandin-properties in allodynia suggests a convergence of cellular 
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events by which low- and high-threshold input are processed. Thus, the enhancement of: 
a) glutamate release; b) NMDA-mediated Ca2+ influx; c) activation of cyelooxygenase; 
and d) prostaglandin synthesis may comprise synaptic events beginning immediately after 
nerve injury, which initiate the subsequent and more complex changes leading to 
permanent (prostaglandin-independent) allodynia. 
In the present study, we used the rat spinal nerve ligation model to test the 
hypothesis that mechanical allodynia is comprised of an early spinal prostaglandin-
dependent phase, the disruption of which prevents the establishment of delayed 
(prostaglandin-independent) allodynia. 
3.2 MATERIALS AND METHODS 
All studies were conducted in accordance with the guidelines of the Institutional 
Animal Care Committee of Memorial University of Newfoundland, St. John's, NF, 
Canada. 
In Vivo Experiments 
Animals: As described in section 2.2. 
Intrathecal Catheterization: Intrathecal microdialysis catheters were constructed 
and implanted as described in section 2.2. Drugs were delivered intrathecally through a 
separate channel of the microdialysis catheter. Rats displaying normal motor behaviour 
were housed separately and allowed to recover for three days before spinal nerve ligation. 
A laminectomy was performed at the end of the experiments to visually confirm the 
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position of the i.t. catheter (except for rats used in the in vitro experiments whcre this was 
not feasible). No animal had to be excluded from the results because of an improperly 
positioned catheter. 
Spinal Nerve Ligation: As described in section 2.2. 
Microdialysis: As described in section 2.2 
Testing: Quantification of mechanical allodynia was performed as described in 
section 2.2. The investigator (MPH) was blinded to the identity of the treaUTIents 
throughout the study. 
Drugs: Drugs, dilutions and injection techniques were similar to that described in 
section 2.2., except SC·51322 was not used here. 
In Vitro Experiments 
Tissue Preparation: Rats were anesthetized with urethane (1.5 glkg 
intraperitoneal) and killed by decapitation. The spinal cord was removed immediately 
using the hydraulic technique (Meikle and Martin, 1981). After careful removal of the 
dural and arachnoid membranes, the lumbar region was visually identified, excised, and 
mounted on cutting blocks. The tissue was submersed in suerose·modified artificial 
cerebrospinal fluid aerated with 95% 02/5% C02 and sectioned using a vibratome. 
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Spinal cord slices (600-800 }lm) were placed in artificial cey cbrospinal fluid aerated with 
95% 0 2/5% CO2 and stored at room temperature. 
Determination of Glutamate Concentration: T he basal and PGErevoked 
release of glutamate fTom spinal cord slices was detennined using a modified enzymatic 
assay (Nicholls et aI., 1987; Bezzi et aI., 1998). Briefly, th e slices were transferred from 
the storage buffer to a 1 x I em cuvette containing (m.M): NaCI (120), KCl (3.1), 
NaH2P04 (1.25), HEPES (25), glucose (4), MgCh (1), CaCh (2), glutamate 
dehydrogenase (40 Vlml; BioVectra, Charlottetown, Canad a), and nicotinamide adenine 
dinucleotide phosphate (I); pH 7.4. The cuvette was placed in a temperature-controlled 
Shimadzu RF-1501 spectrofluorometer. The contents of the cuvette were continuously 
mixed using a magnetic stirrer and the temperatuTe hel d at 37°C. HEPES buffer 
containing the tissue slice was oxygenated with 100% 0 2 throughout the experiment. 
Glutamate released from the tissue was immediately ox.idized to a-ketoglutarate by 
glutamate dehydrogenase thereby preventing neuronal reuptake of glutamate (Bezzi et aI., 
1998; Vesce et aI., 1997). The reduced fonn of nicotin amide adenine dinueleotide 
phosphate generated from this Teaction, was quantitated using spectrofluoTometry 
(excitation: 335 nm; emission: 430 nm; delay <I s). Prostagl andin E2 (PGE2; Biomol) was 
initially dissolved in ethanol and evaporated under 100% nitrogen gas. It was then re-
dissolved in nonnal saline, diluted with the same to yield the desired concentrations, and 
added directly to the cuvette using a mierosyringe. Each concentration of PGE2 was 
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tested using a separate slice such that a full PGE2 concentration-response curve was 
detennined in each animal. Standard curves were prepared on each day of analysis. 
Statistical Analysis: All data are reported as the mean ± SEM. Paw withdrawal 
thresholds are presented in grams. The concentration of PGE2 in microdialysis samples 
([PGE2)d;.lysat~) is presented as either pmoVrnl or the percent of baseline. Glutamate 
release is reported as pmoVminlmg protein. Statistical testing was perfonned using 
Sigmastat® 2.03 for Windows® (SPSS Inc., Chicago, USA). Pre- and post-treatment 
values were compared within each treatment group using one-way repeated measures 
analysis of variance followed by the Newman-Keuls test. Comparisons were also made 
across all drug- and vehicle-treated groups at each time point using one-way completely 
randomized analysis of variance followed by the Newman-Keuls test. Concentration-
response analysis was perfonned using methods from Tallarida and Murray (1987). P < 
0.05 was considered to be statistically significant. 
3.3 RESULTS 
Rats undergoing L51L6 spinal nerve ligation displayed a significant decrease in 
paw withdrawal threshold (from ~15 g to:S;4 g) beginning one day later (fig. 3.IA). This 
enhancement in mechano-sensitivity remained stable for at least 20 days, and was 
confined to the plantar surface of the hind paw ipsilateral to nerve ligation. In addition, 
the affected hind paw was often kept in an elevated and cupped position presumably to 
minimize contact with the cage floor. These rats were otherwise healthy, exhibiting 
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normal feeding behaviour and regular weight gain. The paw withdrawal thresholds of all 
sham-operated rats remained unchanged from pre-surgical values (fig. 3.1 A). The basal 
concentration of PGE2 in spinal dialysate samples, which ranged from 1.6 ± 0.4 to 4.1 ± 
1.4 pmoVrnl, was unchanged from pre-ligation values up to 20 days after nerve ligation 
(fig.3.1B). 
Brushing the plantar surface of the left hind paw had no effect on PGE2 
concentration prior to nerve ligation (fig. 3.2A). In contrast, brushing evoked a 
significant increase in PGE2 concentration in spinal dialysate on days I (259 ± 59% of 
baseline; fig. 3.28), 2 (257 ± 62%; fig. 3.3A), and 5 (199 ± 34%; fig. 3.38) after nerve 
ligation as compared to baseline or the corresponding sham-control. PGE2 concentration 
peaked during brushing and declined gradually (up to 30 min) thereafter. Brushing was 
without effect 10 and 20 days after nerve ligation (fig. 3.4A,B). The overall time-course 
of PGE2 concentration in spinal dialysate from nerve-ligated and sham-operated rats is 
summarized in figure 3.5. 
74 
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Post-Operative Day 
Day After Ugation 
Figure 3.1 A) Left hind paw withdrawal thresholds of ani mals used in the 
microdialysis experiments. All values for the ligated group are significantly 
different from pre-ligation values (p < 0.001 (or ligated group; p::O.659 for sham 
gro up). Each point represents mea n ± SEM of 6-7 animals. 0) Basal PGEl 
concentrations in spinal dialysate before and after nerve ligation. Spinal dialysate 
sa mples were collected immediately before brushing the left hind paw (see 
Methods). Each bar represents the mean ± SEM of 6-8 animals. There were no 
significa nt differences among the groups (p:::O.190). 
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Figure 3.2. PGEl concentration in spinal dialysate before and after brushing (BR) 
the left hind paw of nerve-ligated or sham-operated rats. Before ligation, brushing 
of the plantar surface of the left hind paw evoked no detectable increase in the PGE2 
concentration in spinal dialysate (A; p=O.889 for Ligated group; p=O.219 for sham 
gro up). In contrast, 1 day after nerve ligation the same stimulus applied to the left 
hind paw evoked a significant increase in PGEl concentration compared to baseline 
or the corresponding sham controls (B; p=O.037 for ligated group; p=O.894 for sham 
group). Each bar represents the mean ± SEM of 6-7 animals. 
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Figure 3.3. PGEz concentration in spinal dialysate before and after brushing (BR) 
the left hind paw of nerve-ligated or sham-operated rats. Brushing the left hind 
paw evoked a significant increase in PGEz concentration compared to baseline or 
the corresponding sham controls on day 2 (A; p=O.044 for ligated group; p=O.333 
for sham group), and 5 (B; p::::O.029 for ligated group; p=O.718 for sham group) after 
nerve ligation. Each bar represents the mean:t: SEM of 6-7 animals. 
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Figure 3.4. PG~ concentration in spinal dialysate before and after brushing (BR) 
the left hind paw of nerve-ligated or sham-operated rats. Brushing had no effect on 
days 10 (A; p=0.177 for ligated group; p=O.971 for sham group) or 20 (B; p=O.S89 
fo r ligated group; p=0.9S2 for sham group). Each bar represents the mean ± SEM 
of 6-7 animals. 
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Figure 3.5. The time-course of the brush-evoked changes in spin al dialysate PGEl 
concentration from nerve-ligated or sham-operated rats. Each bar represents the 
sum of the IPGE1 1dlalyptt from 0-90 min (see fig. 3.2) for each experimental day. The 
brush-evoked changes in IPG E2Idlaly,.IO on days 1,2 and 5, but not 10 and 20 post-
ligation, were significantly different (rom both pre-ligation and the corresponding 
sham control values (* p "" 0.005 for ligated group; p=O.303 for sham group). 
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Figure 3.6. PGE2 concentration in spinal dialysate before and afler brushing 
(DR) the contralateral (right) hind paw of nerve-ligated or sham-operated rats 5 
days after surgery. The IPGEzldl.lynlt was unchanged from baseline in both groups 
(p=O.947 for ligated group; p=O.741 for sham group). Each bar represents the mean 
± SEM 0(6-7 animals. 
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Figure 3.7. The effect of intrathecal S(+)- and R(-)-ibuprofen (IBU) on the brush 
(BR}-evoked change in PGE1 concentration in spinal dialysate (A) and mechanical 
anodynia (B) using nerve-ligated and sham-operated rats. All experiments were 
performed 5 days after surgery, and each bar represents the mean ± SEM of 6-8 
animals. In panel A, S(+)- or R(-)-ibuprofen (100 ~g) was injected 60 min before 
brushing the left hind paw. Asterisks indicate a significant difference from baseline 
or the corresponding control (p<O.OOl for ligated group; p=0.309 for sham group). 
In panel B, S(+)- or R(-}-ibuprofen (100 ~g) was injected at time 0 followed by von 
Frey testing al 40, 60 and 80 min. Asterisks indicate a significant difference from 
R(-)-ibuprofen group (p<O.OOl for both 40 min and 80 min groups). 
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Figure 3.8. Left hind paw withdrawal thresholds up to 24 days after spinal nerve ligation. 
Animals either received 2 (4 hour treatment; .) or 4 (8 hour treatment; A) post-operative 
doses of 100 ",g S(+)-Ibuprofen (A), 100 ",g R(.)-ibuprofen (B), or 5",1 dimethyl sulfoxide (C) 
given intrathecally beginning 2 h after spinal nerve ligation was completed. Each point 
represents the mean ± SEM of 6 animals. All values for the 4 h S(+)-ibuprofen treatment 
group are significantly different from pre-ligation values and the corresponding 8 h 
treatment group (p<O.OOl). No value for the 8 h S(+)-ibuprofen treatment group was 
different from the pre-ligation value (p=0.429). All values for the R(-)-ibuprofen (p<O.OOI 
for 4h and 8h groups) and dimethyl sulfoxide (p<O.OOI for 4h and 8h groups) treated groups 
were significantly different from pre-ligation values. 
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Brushing the contralateral (right) hind paw of either nerve-ligated or sham-operated rats 
had no effect on PGE2 concentrations 5 days after surgery (fig. 3.6). Pretreatment with i.t 
S(+)-ibuprofen (100 I-1g), a dose that reversed tactile allodynia 5 days after nerve ligation 
(fig. 3.7B), significantly attenuated the brush-evoked increase in PGEz concentration in 
nerve-ligated rats (fig. 3.7A). R(-)-ibuprofen (100 I-lg) had no effect on either the brush-
evoked concentration ofPGE2 (fig. 3.7A) or tactile allodynia (fig. 3.78). 
To test the relevance of spinal prostanoid synthesis to allodynia, separate groups 
of rats were treated with 100 I-lg of i.t. S(+)-ibuprofen, R(-)-ibuprofen, or vehicle 
beginning 2 h after spinal nerve ligation (fig. 3.8, 3.9). Rats treated with i.t. S(+)-
ibuprofen over an 8-h period (4 i.t. injections of 100 ~g given every 2h) exhibited nonnal 
posture (no cupped hind paw) and paw withdrawal thresholds (~15g) for alleasl24 days 
after nerve injury. Brushing the ipsilateral hind paw had no effect on the (PGE2]dialysa.,c in 
these same animals (fig. 3.9A1B). 
In contrast, ligated rats treated with i.t. S(+)-ibuprofen over 4h (100 ~g every 2h 
for a total of2 injections; fig. 3.8A), R(-)-ibuprofen over 4 h or 8 h (100 ~g given every 2 
h for a total of 2 or 4 injections, respectively; fig. 3.8B), or vehicle using the same 
treatment schedules (fig. 3.8C) developed allodynia that was indistinguishable from 
untreated, ligated rats in terms of paw withdrawal threshold (Figure lA), and brush-
evoked changes in behaviour and [PGEZ]dialysalc (fig. 3.9A-C). Area-under-the-curve 
analysis revealed no difference (p=0.65) in tbe brush-evoked (PGE2]dialy,alc of the R(-)-
ibuprofen treated group (fig. 3.98) versus ligated, untreated rats (fig. 3.3A). The ability 
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of brushing to increase [PGE2)di. lysate in the R(-)-ibuprofen (allodynic) group was lost by 
day 10 (fig. 3.9C), similar to that in ligated, untreated (allodynic) rats (fig. 3.4A). 
Figure 3.9. PGE2 concentration in spinal dialysate before and after brushing (BR) 
the left hind paw of nerve-ligated rats. Before ligation, BR of the plantar surface of 
the left hindpaw evoked no detectable increase in the PGEl concentration in spinal 
dialysate (A; p=O.954 for S(+)-ibuprofen group; p=O.987 for R(-)-ibuprofen group). 
In contrast, on day 2 post-ligation, the same stimulus applied to the left hind paw of 
rats treated post-operatively with R(-)-ibuprofen evoked a significant increase in 
PGEz concentration compared to baseli.ne or the corresponding S(+)-ibuprofen-
treated animals (B; * p=O.OIO); no detectable increase was observed in rats treated 
post-operatively with S(+)-ibuprofen (B; p=0.555). Brushing had no effect on day 10 
in either group (C; p=0.912 for S(+)-ibuprofen group; p=0.966 for R(-)-ibuprofen 
group). Each bar rep resents the mea n ± SEM of6-7 animals. 
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To detennine if allodynic animals also exhibit phannacodynamic changes to the 
response evoked by spinal prostaglandins, separate groups of rats undergoing spinal 
nerve ligation were treated with i.t. R(-)- or S(+)-ibuprofen over 8 h (100 Ilg given every 
2 h for a total of 4 injections). The concentration-response effect of PGE2 on glutamate 
release was compared using spinal cord slices prepared from allodynic and non-allodynic 
animals. PGE2 evoked release from the slices of sham-operated [non-al lodynic] rats in a 
concentration-dependent manner, resulting in a bell-shaped concentration-response curve 
(fig. 3.10; Table 3. 1). Whereas the PGE2 concentration-response curves of ligated 
[untreated) and ligated [R( -)-ibuprofen treated] rats displayed dramatic leftward shifts 
from control, there was no difference between sham-operated [non-allodynic] and ligated 
[S(+)-ibuprofen (8 h) treated, non-allodynic] rats (fig. 3.10; Table 3.1). 
Table 3.1. ECso values (95% co nfidence intervals) of PGEl on Glutamate Release 
from Spinal Cord Slices 
Sham-operated (non-allodynic) S(+)-ibuprofen treated (non-allodynic) 
Ligated (allodynic) R(-)-ibuprofen treated (allodynic) 
8.9xlO· 1S (4.3xlO-1S _ 1.9xlO·14) M 2.0xlO·14 (l.lxlO·14 _ 3.7x IO·14) M 
Note: All ammals underwent LSfL6 spmal nerve ligatIOn except the sham-operated group. 
Spinal cord tissue was harvested from rats J days after spinal nerve injury. 
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Figure 3.10. PGE2-evoked glutamate release using spina l cord slices from sham-
operated and nerve-ligated rats 3 days after surgery. The addition of PGE2 
produced concentration-dependent glutamate release from spinal cord slices of 
sham-operated (non-allodynic) animals (see Table 3.1 for ECso and 95% confidence 
intervals of each group). This effect was significantly enhanced (Iefhvard shift) in 
slices from ligated (allodynic) rats. The concentration-response curve using slices 
from ligated rats treated with S(+)-ibuprofen (4 intrathefal doses of 100 pg every 2 
h beginning 2 h after ligation), which prevented allodynia (see fig. 3.8), was not 
significantly different from the sham-operated group. In contrast, slices from 
ligated rats treated with R(-)-ibuprofen, which had no effect on allodynia (see fig. 
3.8) yielded a concentration-response curve that was not significantly different from 
ligated, untreated (allodynic) rats. Each point represents the mean ±SEM of at least 
5 animals (5-14 slices). 
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To determine whether this protective effect resulted from early cyclooxygenase-I 
andlor cyclooxygenase-2 inhibition, rats were treated with i.t. SC-560 or SC-236 (100 
Ilg) beginning 2 h after spinal nerve ligation. Paw withdrawal thresholds in ligated rats 
treated with either an 8h regimen of i.t. SC-560 were slightly but not significantly 
decreased compared to pre- ligation values for up to 20 days (fig. 3.11 A). For the 4 h 
treatment, paw withdrawal thresholds on days 2 and 5 were statistically different from 
pre-ligation values but never fen below 9 g. In contrast, animals treated with i.t. SC-236 
(4 or 8 h regimen) displayed a time course of paw withdrawal threshold (fig. 3.1 18) 
unchanged from ligated, untreated rats (fig. 3.IA); all time points were significantly 
different from pre-ligation values. 
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Figure 3.11. Left hind paw withdrawal thresholds up to 21 days after spinal nerve 
ligation. Animals either r eceived 2 (4 hour treatment ; .) or 4 (8 hour treatment; 
A) post-operative doses of 100 pg SC-560 (A) or 100 Ilg SC-236 (B) given 
intrathetally beginning 2 h after spinal nerve ligation. Each point represents the 
mean ± SEM of 6 animals. Asterisks indicate signifkant difference from pre-
ligation values (p =0.013 for 4h SC-236 group; p=O.009 for 8h SC-236 group; 
p=O.022 for 4h SC-560 group; p=O.235 for 8h SC-560 group). 
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3.4 DISCUSSION 
Ligation of the left L5/L6 spinal nerves produced a robust sensitization to 
innocuous mechanical stimulation on the plantar surface of the left hind paw beginning I 
day later. This was indicated by the: I) marked decrease in the paw withdrawal threshold 
«4 g); 2) brush·cvoked nociceptive-like behaviour; and 3) concurrent stimulus-evoked 
increase in [PGE2]dialysale . The area of sensitization remained highly circumscribed over 
time, and was absent in sham-operated controls. Brushing the hind paws of sham-
operated animals, or outside the affected derma tomes (including the contralateral hind 
paw) of ligated rats was without effect. These results indicate that prostanoid synthesis is 
recruited in the spinal cord of L51L6 nerve-ligated animals: a response that appears to be 
triggered by brushing (a stimulus that elicited allodynic behaviour in the same animals 
during the prostaglandin-dependent phase of allodynia). This brush-evoked release of 
PGE2. which declines by day 5, was absent on day 10 even though brush-evoked 
allodynia persisted for up to 20 days independent of any detectable change in 
[PGE2]diaIY ... le . 
The cOllllection between allodynia and spinal prostaglandins appears to involve 
more than just the emergence of brush-evoked prostanoid synthesis. There was also a 
marked decrease in the ECSl) of PGE2-evoked glutamate release in slices prepared from 
the affected (L51L6) segments of allodynic rats compared to either thoracic slices from 
the same animals (data not shown), or slices of L51L6 spinal cord from sham-operated 
controls. The concentration-response curve for PGE2-evoked glutamate release was 
bell-shaped, similar to that reported by Nishihara et al. (1995) using spinal cord 
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synaptosomes and by Uda and collegues (1990) who reported this phenomenon with 
prostaglandin-evoked nociceptive behavior in mice and by that. Whether this decrease in 
response to high PGE2 concentrations has physiological importance is yet to be 
determined. Regardless, glutamate has has a recognized role in neuropathic states, 
including the NMDA-receptor coupled activation of phopholipase A2, NOS, COX, and 
various kinases (Yaksh et ai., 1999; Yaksh, 1999; Yang ct aL, 1996), many of whose 
products diffuse into the extracellular space to enhance neurotransmitter release. The 
mechanism(s) underlying the increased potency of PGE2 are currently being investigated 
but could include the ampli fication of spinal prostaglandin synthesis in nelVe-injured 
segments where increased expression of cyc100xygenase-2 has been shown to occur 
(Zhao et ai., 2000). Such a pharmacodynamic ehange in the affected spinal segments of 
demonstrably allodynic animals has not, to our knowledge, been previously reported. 
Allodynia and spinal prostaglandins appear to be functionally linked in the early 
post-injury period. Brush-evoked spinal PGE2 release and allodynia were significantly 
attenuated by i.t. S(+)-ibuprofen (a eyc1ooxygenase-l/cyc1ooxygenase-2 inhibitor), but 
not R(-)-ibuprofen, in the spinal nelVe ligation model (see chapter 2; also Hefferan et ai., 
2003a). The relevance of spinal prostaglandins to the development of allodynia is further 
strengthened by the results of the present study. When given early after ligation, all rats 
treated with 100 ~g of S(+)-ibuprofen developed none of the characteristic features of 
allodynia for up to 25 days. Paw withdrawal thresholds remained normal (~15 g), 
brushing had no effect on the [PGE2]dialysalo, and there was no change in PGEz-evoked 
glutamate release from spinal cord slices, compared to sham-operated controls. In 
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contrast, R(-)-ibuprofcn, an inactive cyc100xygenase inhibitor and control treatment in 
these experiments, had no protective effect whatsoever. R(-)-ibuprofen has been shown 
to inhibit the transcription factor, NFKB in vitro (Scheuren et aI., 1998; Grilli et al., 
1996); a factor known to regulate the expression of cyc1ooxygenase-2 in macrophages 
and human gingival fibroblasts (Mestre et aI., 2001; Nakao et aI., 2000). To the extent 
that up-regulation of cyc1ooxygcnasc-2 after injury is important in the establishment of 
allodynia (a factor yet to be confirmed), then the inhibition of NfKB by R(-)-ibuprofen 
would be predicted to attenuate allodynia. No such effect was observed but further 
studies are required to address this possibility. Overall, the results of these experiments 
support the hypothesis that spinal prostaglandins are critical factors in the initiation of 
changes (e.g. central synaptic excitability and neuronal sensitization) leading to both 
prostaglandin-dependent and prostaglandin-independent allodynia. The protective effcct 
ofS(+)-ibuprofen was also dependent on the duration of treatment (only the 8 h regimen 
was effective) suggesting that prostaglandin synthesis must be inhibited for a minimum 
period of time following ligation to effectively prevent/interrupt the events leading to 
allodynia. The results of this study arc in general agreement with and build upon the 
preliminary work of Zhao et al. (2000) who showed that the non-selective 
cyc100xygenase inhibitor, indomethacin, given spinally 2 h after spinal nerve ligation, 
partially attenuated the development ofallodynia for up to 4 weeks in the rat. 
To extend this work, cyc1ooxygenasc-l and cyc1ooxygenase-2 selective inhibitors 
were utilized to provide information about the isozyme(s) catalyzing spinal prostaglandin 
synthesis in the nerve-injured cord. The doses of SC-236 (cyc1ooxygenase-2 selective) 
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and SC-560 (cyclooxygenase-I selective) were chosen from previous dose-response 
studies in our laboratory (see chapter 2; also Hefferan et al., 2003a). In that study, we 
showed a dramatic difference in the inhibitory effect of SC-236 and SC-560 on 
established allodynia using near equi-molar i.t. doses suggesting that isozyme-selectivity 
is maintained at the doses used. In the present study, the contrast in effects with SC-560 
and SC-236 was also striking. Whereas SC-560 (both 4 and S h treatments) prevented the 
emergence of all features of allodynia, an effect comparable to that ofS(+)-ibuprofen (Sh 
treatment), SC-236 (4 or S h treatment) was totally ineffective. These results indicate that 
cyclooxygenase-I, known to be constitutively expressed in the spinal cord (Vanegas and 
Schaible, 2001), catalyzes the synthesis of prostaglandins in the period immediately 
following ligation. It is this early synthesis that appears necessary for the development of 
both prostaglandin-dependent and prostaglandin-independent allodynia. This early role 
for COX-I is also suggested by the work of Zhu and Eisenach (2003) who report 
increases in COX-} IR within 4 days after peripheral nerve injury. In contrast, inducible 
cyc100xygenase-2, which is known to be up-regulated 24h after ligation (Zhao et al., 
200 I), appears to be important in maintaining prostaglandin-dependent allodynia; a stage 
when cyc1ooxygenase-1 inhibitors are largely ineffective (see chapter 2; also Hefferan et 
aI., 2003a). Thus, cyclooxygenase-2 may need to achieve suffic ient expression over 
time. The differential localization of constitutive cyclooxygenase- I and constitutive 
cyc1ooxygenase-2 reported in primary afferent tenninals of the rat (Willingale et al. 
1997) might also explain the early sensitivity to cyclooxygenase- I inhibitors. 
An obvious question arising from these experiments is whether allodynia would 
have developed without drug treatment (e.g. unsuccessful nerve ligation). This outcome 
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is unlikely cons idering that the protective effect was stereo-spec ific, cyclooxygenase-I 
selective, and treatment duration-dependent. Moreover, greater than 90% of naive 
animals undergoing L5/L6 spinal nerve ligation in our laboratory develop allodynia 
within I day of surgery; a result comparable to that reported by Chaplan et al. (1994). 
Thus, the unifonn failure of nerve ligation within an experimental group is improbable 
and inconsistent with the results of this study. These data indicate that treatment with 
spinal cyclooxygenase inhibitors early after ligation prevents, or at the very least 
significantly delays (>25 days), the emergence of prostaglandin-dependent and 
prostaglandin-independent allodynia. 
Figure 3.12 is a proposed model of the early (synaptically-mediated) events 
effecting prostaglandin-dependent and prostaglandin-independent allodynia following 
L51L6 spinal nerve ligation. Glutamate, released from the central tenninals of primary 
afferent fibres beginning immediately after nerve injury (Kawamata and Omote, 1996; 
Farooque et al., 1996), activates post-synaptic NMDA receptors; an essential step in 
central sensitization and allodynia (Kajander et aI., 1992; Yoon et aI., 1996). Subsequent 
intracellular events, including a rise in Ca2+ concentration and the release of arachidonic 
acid via PLA2, trigger the early synthesis of spinal prostaglandins by constitutive 
enzymes (cyclooxygenase-I >cyc10oxygenase-2). This immediate release of 
prostaglandins following injury is probably represented by the near 2-fold increase in 
resting [PGE2]dialysatc one day after injury (see fig. 3.1 b). although this increase did not 
reach statistical significance (p=O.I90). Upon diffusion to the extracellular space, spinal 
prostaglandins enhance the excitability of adjacent cells (Willingale et al., 1997; Baba et 
aI., 200 1), and feed back to reinforce glutamate release (Ferreira and Lorenzetti, 1996; 
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Hingtgen et aI., 1995; Vasko et a!., 1994). Sustained NMDA receptor activation initiates 
the expression of inducible cyciooxygenase-2 (Vanegas and Schaible, 2001), thereby 
enhancing the capacity for stimulus-evoked prostaglandin synthesis in the spinal cord 
(cyclooxygenase-2>cyciooxygenase-l) and the emergence of prostaglandin-dependent 
allodynia (see chapter 2; also Hefferan et aI., 2003a,b). Over the next few weeks, 
prostaglandin-dependent allodynia recedes leaving long-term, prostaglandin-independent 
allodynia (Lashbrook ct aI., 1999 ; Zhao et aI. , 2000). The latter may reflect phenotypic 
changes in primary atTerents, sprouting of primary atTerents into outer laminae, and/or 
altered gene regulation (Wakisaka et al., 1992; LaMotte et aI., 1991; Woolf et al., 1992; 
Herdegen et al., 1992; Cameron-Curry et aI., 1991). The ability of cyciooxygenase 
inhibitors to prevent the emergence of both prostaglandin-dependent and prostaglandin-
independent allodynia strongly suggests that these two states are related. 
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Figure 3.12. A proposed model of the early (synaptically-mediated) events in the 
spinal cord effecting aUodynia following LSIL6 spinal nerve ligation. Glutamate, 
released from the central terminals of primary afferent fibres beginning 
immediately after ligation, activates post-synaptic NMDA receptors. Subsequent 
intracellular events (omitted for clarity), including a rise in the CaH concentration 
and activation of PLAh trigger the early synthesis of spinal prostaglandins by 
constitutive activity (cyclooxygenase-l>cyclooxygenase-2). In the extracellular 
space, spinal prostaglandins diffuse to adjacent cells to enhance glutamate release 
and cell excitability (post-synaptic effect). Sustained NMDA receptor activation 
initiates the delayed expression of inducible cyclooxygenase-2 in the spinal cord 
(--). Within 24 h of ligation, central sensitization combined with the enhanced 
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capacity for prostaglandin synthesis (cyclooxygenase-2>cyclooxygenase-l) results in 
the emergence of temporary. prostaglandin-dependent allodynia. Over the next few 
weeks ( .•.•.• ). prostaglandin-dependent allodynia recedes leaving long-term allodynia 
that is independent of spinal prostaglandins. This may reflect phenotypic changes 
in primary afferents, sprouting of primary afferents into outer laminae, altered gene 
regulation, and changes in expression of critical receptors, ion channels, and/or 
enzymes. 
In conclusion, the results of this study provide evidence that spinal 
prostaglandins, synthesized immediately after spinal nerve ligation, are cri tical in the 
development of prostaglandin-dependent and prostaglandin-independent allodynia, and 
that their early pharmacological disruption affords protection against this neuropathic 
state. They build upon and are consistent with previous work demonstrating the 
prostaglandin-dependent nature of allodynia in this model (see chapter 2; also Zhao et aI., 
2000; Hefferan et aI., 2003a), but arc seemingly at odds with anecdotal reports that non-
steroidal anti-inflammatory drugs provide little, if any, benefit to patients with allodynia. 
How then can this apparent contradiction be resolved? Our data indicate that the timing 
of treatment, the type of cyclooxygenase inhibitor used, and perhaps the route of 
administration, are critical factors influencing the effectiveness of non-steroidal anti-
in[]ammatory drugs. not in relieving neuropathic pain per se, but in preventing its 
emergence. They suggest that non-steroidal anti-inflammatory drugs would need to be 
given early (hours) after injury, following which their clinical value would decline. The 
latter prediction is seemingly consistent with current clinical experience. It should also 
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be noted that since the current research examined evoked nociceptive responses, not 
indices of chronic pain, it is possible that the clinical implications for the results would 
only benefit patients with evoked, and not chronic pain. While it is clear that further 
research is needed to clarify these issues, the potential implications of this research for 
clinical neuropathic pain are exciting. 
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4.0 INTERACTION OF SPINAL NITRIC OXIDE AND PROSTAGLANDINS 
AFTER L51L6 SPINAL NERVE LIGATION IN T HE RAT: AN 
ISOBOLOGRAPHIC ANALYSIS 
Michael P. Hefferan and Christopher W. Loomis, Anesthesiology 2004; 100: 161 1-1614 
4.1 INTRODUCTION 
Spinal prostaglandins appear to be important in the pathogenesis and early 
maintenance (hours-days after nerve injury) of experimental allodynia (see chapters 2 and 
3; also Parris et al., 1996; Zhao et at, 2000; Hefferan et al., 2003a,b). This relationship is 
consistent with: a) cyc100xygcnasc and prostanoid receptor localization in the ouler 
laminae oflhe spinal dorsal hom (Beiche et aI., 1996; Willingale et al., 1997; Vane et ai., 
1998); b) exogenous prostaglandins (i.e. Lt.) eliciting allodyn ia-l ike behaviour in 
otherwise nonnal animals (Uda et al., 1990; Minami e( aI., 1995; Ferreira SH, Lorenzetti, 
1996); and c) brush-evoked allodynia and spinal PGE2 release in nerve-injured, but not 
sham-operated, rats (see chapters 2 and 3; also Hefferan et ai, 2003a,b). It is also 
supported by recent studies showing that i.t. cyclooxygenase inh ibitors, given 2-8 h after 
L51L6 spinal nerve ligation, prevented the development of allodynia for at least 20 days 
in the rat (sec chapter 3; also Zhao et aI., 2000; Hefferan et aI., 2003b). A similar 
connection between spinal NOS and neuropathic pain has emerged (Hao and Xu, 1996; 
Yoon et aI., 1998; Dolan and Nolan, 1999; Park et aI., 2000; Milne et aI., 200 1), 
including the increased expression of neuronal NOS in the spinal cord after L51L6 spinal 
nerve ligation (Dolan and Nolan, 1999). These reports. combined with the apparent 
regulation of cyclooxygenase expression and prostaglandin synthesis by NO (Bredt and 
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Snyder, 1992; Mollace et aI., 1995; Haley et al., 1992; Garthwaite et aI., 1988), raise 
questions about the interaction between spinal NO and prostaglandins in abnormal pain 
states. The nature of this interaction could have significant implications in the treatment 
of neuropathic pain. An additive or a synergistic interaction would most likely require 
different treatment regimens. In the present study, we investigated this interaction using 
selective NOS- and cyclooxygenase-inhibitors in the L51L6 spinal nerve ligation model. 
4.2 METHODS 
All studies were conducted in accordance with the guidelines of the Institutional 
Animal Care Committee of Memorial University of Newfoundland, SI. John's, NF, 
Canada. 
Animals: As described in section 2.2. 
Intrathecal catheterization: As described in section2.2. 
Spinal Nerve Ligation: As described in section2.2. 
Testing: Quantification of mechanical allodynia and drug-induced changes in 
paw withdrawal thresholds were performed as described in section 2.2. 
Experimental Protocols: Dose-response curves for S(+)-ibuprofen and L-
NAME were determined in separate groups of rats. For combination studies, a molar 
ratio of 1:5 was used based on the ED40 values of each agent [S(+)-ibuprofen=o87 nmol 
(18 ~g); L-NAME::=445 nmol (120 ~g)l (see chapter 2; also Hefferan et aI., 2003a). Dose 
ratios of S(+)-ibuprofen:L-NAME were: 10:50, 30:150, 100:500, or 300:1500 nmol 
(2:13,6:40,21:135, or 62:404 ~g. respectively). Eaeh drug was delivered intrathecally, 
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with a 20-min dclay bctwcen S(+).ibuprofen and L-NAME (to correct for the difference 
in the time of peak effect). In a separate expetiment, the order was reversed to control for 
the sequence of administration. S(+)-ibuprofcn (active sterco-isomer) was dissolved in 
100% DMSO and diluted with saline upon injection for a final DMSO concentration of 
50%; L-NAME and aminoguanidine were dissolved in saline and diluted with the same. 
All drugs were purchased from Research Biochemicals Intcrnational (Natick, MA, USA). 
Data Analysis: As described in section 2.2. 
4.3 RESULTS 
Tight ligation of the L5/L6 spinal nelVes produced touch-evoked allodynia 
manifested as a significant reduction in the PWT (from ~ 15 g to 1-3 g) of the ipsilateral 
hind paw, and posturing to protect the sensitized area. PWTs in all sham-operated rats 
remained unchanged from pre-surgical values (~15 g). 
Intrathecal L-NAME produced dose-dependent but incomplete reversal of 
allodynia (57% of maximum) over the 30-300 I1g range. Figure 4.1A shows the time-
course of paw withdrawal threshold following the L .. injection of L-NAME. The onset 
of effect was 20-40 min after injection and peaked at 40-60 min. Dose-response analysis 
using the peak effect of each dose yielded a linear relationship over the range of 30-300 
).1g (fig. 4.18); no change in efficacy of L-NAME was noted over the 2-12 day 
experiment petiod. A dose of 1000).1g yielded no further reversal ofallodynia (data not 
shown). Intrathecal aminoguanidine (an inhibitor of iNOS; 30-300 ).1g) was largely 
ineffective in reversing allodynia (fig. 4.2A1B). Neither lumbar injections of D-NAME 
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(100 ~g; fig. 4.1A/B), mid-cervical injections of L-NAME (100 ~g; fig. 4. IB), DMSO 
nor saline had any effect on PWT in ligated rats (see chapter 2; also Hefferan et aI., 
2003a). While not systematically tested, no drug tested seemed to elicit adverse motor 
effects, with injected rats having nonnal gait and level of alertness. 
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Figure 4.1. Intrathecal L-NAME dose-dependently reversed allodynia in the L51L6 spinal 
nerve ligation model. Time-course (A) and dose-response curve (8) for intrathecal L-
NAME. In panel A, each asterisk indicates a significant difference from control (time 0; 
p<O.OOI for 30 JIg group; p-o.OO9 for 100 Ilg group; p"'0.003 for 300 fJg group). Each point 
represents the mean ± SEM of 6-8 animals. Dose-response experiments were conducted 2-
12 days after nerve ligation. Drug-induced changes in left-paw withdrawal thresholds are 
expressed as % anti-allodynla (see Methods). Dashed lines indicate the 95% confidence 
intervals. The ED50 (95% confidence intervals) ofL-NAME - 212 (112-402) Ilg. The effects 
of intrathecal O-NAME (0 ; lumbar injection) and L-NAME (V; mid-<:ervical inje<:tion) are 
also shown as single points. 
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Figure 4.2. Intrathecal aminoguanidine had no dose-dependent effect on allodynia 
in the L5/L6 spinal nerve ligation model (p:().795 for 30 JIg group; p=0.610 for 100 
JIg group; p=O.597 for 300 JIg group). Time-course (A) and dose-response curve (B) 
for intrathecal aminoguanidine. Each point represents the mean ± SEM of 4-5 
animals. Dose-response experiments were conducted 2-12 days after nerve ligation. 
Drug-induced changes in left-paw withdrawal thresholds are expressed as % anti-
allodynia (see Methods). Dashed lines indicate the 95% confidence intervals. The 
slope of the line was not significantly different from zero (p=0.589). 
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The combination of i.1. S(+)-ibuprofen and L-NAME attenuated allodynia in a 
dose-dependent manner, irrespective of treatment order. Figure 4.3A shows sample time-
courses of both injections orders; the dose-response curves were statistically 
indistinguishab le. S(+)-ibuprofen significantly reduced the EDso of L-NAME from 212 
to 69 Ilg (L-NAME followed by ibuprofen), and increased the maximum anti-allodynic 
effect to 89% (fig. 4.38). Isobolographic analysis revealed an additive interaction with 
the EDsos of the combination falling within the 95% confidence intervals of the 
theoretical additive line (fig. 4.4). Unlike their sequential injection, the co-injection of 
S(+)-ibuprofen and L-NAME yielded inconsistent results (data not shown), possibly 
reflecting their incompatibility in solution, while the 20 min delay between the sequential 
injections would allow the local CSF concentration of the first agent to be suffic iently 
low not to significantly intereact with the second agent. The inactive R(-)-isomcr of 
ibuprofen was without effect (data not shown). 
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Figure 4.3. Addition of intrathecal S(+)-ibuprofen enhanced the anti-allodynic 
effect of L-NAME in the L5fL6 spinal nerve ligation model. Panel A is an example 
of one time course (21 J.1g S(+)-ibu & 135 J.1g L-NAME; others omitted for clarity) 
and panel B is the dose-response curves for the combination studies. Each point 
represents the mean ± SEM of 6-8 animals. Asterisks represent significant 
difference from baseHne (time 0; p=0.002 for 'S(+)-ibuprofen then L-NAME' group; 
p<O.OOI for 'L-NAME then S(+)-ibuprofen' group). Dose-response experiments 
were conducted 2-12 days after nerve ligation. S(+)-ibuprofen was administered 
either 20 min before (_) or 20 min after ( .... ) intrathecal L-NAME. Drug-induced 
changes in left-paw withdrawal thresholds are expressed as % anti-allodynia (see 
Methods). The ED~s and corresponding 95% confidence intervals for each dose-
response curve are shown in the figure. 
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Figure 4.4. lsobologram illustrating the additive interaction between intrathecal L-
NAME and S(+)-ibuprofen in the L5/L6 spinal nerve ligation model. The points on 
the x- and y-axes are the ED40 and 95% confidence intervals of S(+)-ibuprofen and 
L-NAME, respectively. The '" indicates the ED40 and corresponding 95% 
confidence intervals for the combination of L-NAME followed by S(+)-ibuprofen. 
The _ indicates the ED40 and corresponding 95% confidence intervals for the 
combination of S(+)-ibuprofen followed by L-NAME. 
4.4 DISCUSSION 
S(+)-ibuprofen enhanced the effect of L-NAME in the L5/L6 spinal nerve ligation 
model as indicated by the significant increase in both the potency ofL-NAME (>3-fold) 
and the maximum reversal of allodynia (57% to 89%) as compared to L-NAME alone. 
The stereo-specificity of L-NAME and S(+)-ibuprofen suggests that their anti-allodynic 
effects can be attributed to NOS- and cyc1ooxygenase-inhibition, respectively. 
Isobolographic analysis revealed the interaction to be additive at a fixed molar ratio of 
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1:5 (ibuprofen:L-NAME). That the interaction was not significantly affected by the order 
of drug injection indicates that cyc1ooxygenase- and NOS-inhibition was of sufficient 
duration to correct for the difference in peak effects, and that spinal NOS and 
cyc100xygenase pathways were both activated early after spinal nerve injury. 
A spinal NO-prostanoid interaction is consistent with reports of their individual 
effects in neuroapthic pain models. For example, allodynia induced by i.t. NMDA was 
blocked by NOS and cyc100xygnease-2 inhibitors (Dolan and Nolan, 1999). Intrathecal 
L-NAME attenuates both the hyperalgesia elicited by spinal PGE2 (Park et al., 2000), and 
the allodynia induced by spinal strychnine (Milne el al., 2001). Allodynia is also 
partially reversed by spinal cyc100xygenase inhibitors or prostaglandin receptor 
antagonists in the chronic constriction-, i.t. strychnine-, i.t. bicuculline-, and the spinal 
nerve ligation-models (sec chapter 2; also Parris et al., 1996; Hefferan el al., 2003a; Hall 
et al., 1999; Zhang el a1., 2001). In addition, nonnally innocuous brushing elicited spinal 
prostaglandin synthesis and nocifensive behaviours in allodynic, but not sham-operated 
animals; both effects were blocked by i.t. S(+)-ibuprofen (see chapters 2 and 3; also 
Hefferan et al., 2003a,b). These studies underscore the relevance of spinal prostanoids 
and NO to experimental allodynia, and thus their ability to effect, in combination, this 
abnonnal state. 
A spinal NO-prostanoid interaction is also supported by studies investigating the 
relationship between NO- and prostanoid-pathways (O'Banion, 1999; Perez-Sala and 
Lamas, 2001). The genes coding for NOS and cyc100xygenase have identical promoters 
and response elements to NF-JCB and NF-IL6 (Lowenstein et a1., 1993; Xie et a1., 1993), 
and their expression is triggered by similar mediators (Vane et al., 1994; Swierkosz et al., 
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1995). Prostaglandin synthesis was triggered in human fetal fibroblasts, bovine 
endothelial celis, and mouse macrophages exposed to NO donors (Salvemini et aI., 1993; 
Davidge et aI., 1995), while NO potentiated the IL-Ij3 induced upregulation of COX-2 
mRNA and protein in cultured DRG cells (Morioka ct aI., 2002). Inducible NOS has also 
been implicated in the regulation of hepatic COX-2 (Ahmad et aI., 2002). Conversely, 
NOS activity and nitrite levels were increased in murine macrophages treated with PGE2 
(Milano et al., 1995), and ibuprofen inhibited the synthesis of iNOS (mRNA and protein) 
in glial cell cultures at concentrations blocking PGE2 production (Stratman et aI., 1997). 
These reports indicate a bi-directional relationship between distinct pathways that 
contribute to allodynia early after nerve injury. and are consistent with the additive 
interaction reported in the present study. The latter may include the exacerbation of 
nerve injury-induced cell damage through the local formation ofperoxynitrite (Beckmann 
el al.. 1994; Dawson ct al.. 1996), the reaction product of NO + superoxide anion 
(derived from cyclooxygenase). 
In summary. the interaction between spinal NO and prostanoids has been 
characterized in a well-established model of neuropathic pain using isobolographic 
analysis. While it has been well-known that spinal NO and prostanoids exert their pro-
allodynic effects via distinct pathways, interaction, if any, between these pathways has 
not been previously investigated. The additive interaction reported here indicates a 
convergence in their alteration of sensory processing at the spinal level. (f similar spinal 
mechanisms arc at work in clinical neuropathic pain, then a low-dose combination of 
NOS- and cyclooxygenase-inhibitors could be effective in the early treatment of 
allodynia. 
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5.0 GENERAL DISCUSSION 
There are a number of important results arising from this investigation of experimental 
allodynia. 
Following L51L6 spinal nerve ligation, PGE2 concentrations in spinal CSF 
increased significantly in response to brushing orlhe allodynic dermatomes; basal 
concentrations remained unchanged. There was a clear temporal and spatial 
relationship between low-threshold afferent stimulation, PGE2 release, and 
allodynic responses in nerve-injured animals. The results support the hypothesis 
that spinal prostaglandin release and aUodynia depend upon central synaptic 
activity that is driven by input from affected dermatomes. 
Tactile allodynia depended upon spinal prostaglandin activity for 10-12 days after 
spinal nerve ligation. COX-2 was the predominant isofonn responsible for the de 
novo prostaglandin synthesis during this phase. Thereafter, phannacological 
disruption of spinal prostaglandin activity was without effect leaving long-tenn, 
prostaglandin-independent allodynia. 
Spinal nerve ligation triggered phannacodynamic changes to the spinal 
prostaglandin system that are also temporally and spatially correlated to allodynia. 
PGE2-evoked glutamate release was markedly enhanced in the affected spinal 
segments (L5fL6) of al\odynic rats during prostaglandin-dependent allodynia. 
Possible explanations for this effect include an increase in EP receptor-effector 
coupling, and amplification of prostaglandin synthesis in the nerve-injured 
segments where increased expression of COX-2 has been demonstrated. 
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Preliminary experiments in our laboratory showed that pretreating spinal cord 
slices with COX inhibitors before exposure to PGE2 blocked glutamate release 
(unpublished results). Similarly, pretreatment with intrathecal COX inhibitors 
before spinal prostaglandin administration attenuated PGE2-induced allodynia in 
conscious rats (unpublished data). Thus, exogenous PGE2, or prostaglandins 
synthesized in response to exaggerated afferent input may, through a positive 
feedback effect, trigger excess prostaglandin production in the affected spinal 
segments where up-regUlation of eyclooxygenase is known to occur. 
Treatment with i.t. COX-lor non-selective COX inhibitors, beginning 2h after 
nerve ligation, consistently blocked the cmergenee of allodynia. COX-2 inhibitors 
were without effect. Thus, spinal prostanoid synthesis appears to be an early, 
obligatory stcp in the development of this allodynic state, and COXA} is the 
relevant isofonn catalyzing prostaglandin synthesis in the hours immediately 
following nerve injury. This early effect is in addition to the role served by spinal 
prostaglandins once allodynia is established (i.e. during the prostaglandin-
dependent phase). 
Spinal prostanoids and NO, which have discrete pro-allodynic effects, interact 
positively in the spinal nerve ligation modeL Intrathecal S(+)-ibuprofen enhanced 
the anti-allodynic effect of L-NAME. Isobolographic analysis showed this 
interaction to be additive, suggesting a possible convergence of actions at the 
spinal leveL 
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5.1 DIFFERENTIAL EFFECTS OF SC-236, SC-560 AND S(+)-lBUPROFEN 
In these experiments, selective inhibitors of COX-l or COX-2, and non-selective 
COX inhibitors were used to probe the spinal pharmacology of spinal nerve ligation-
induced allodynia. As with all pharmacological approaches, it is possible that the 
apparent differences in the contributions of COX-l and COX-2 in this model may simply 
reflect differences in the potency of SC-236 and SC-560, and thus the degree of enzyme 
inhibition achieved with each drug under the conditions used in this study. As 
summarized in table 2, SC-560 and SC-236 have virtually identical ICs(I values against 
COX-! and COX-2, respectively. and arc 3400 and 32000 times less potent against the 
opposite COX isoform. S(+)-ibuprofen is equipotent against both COX-I and COX-2 but 
considerably less potent than SC-560 and SC-236 at their respective COX isofonns. 
Table 2. IC~o Values Detennined Against Recombinant Human 
Cyclooxygenases (hCOX) 
INHIBITOR hCOX-I hCOX-2 
SC-560 -5nM 160 !!M 
SC-236 17 !!M 5nM 
S( + )-ibuprofen 3.3 !!M 3.8 !!M 
(From Glerse et al.. 1996, Yaksh et aI., 2001) 
On the basis of these data, similar doses of SC-560 and SC-236, delivered identically into 
the lumbar intrathecal space, were used throughout this study. The marked temporal 
differences in sensitivity to these equi-potent drugs following spinal nerve ligation, 
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combined with the observation that S(+)-ibuprofen, a less potent, non-selective COX 
inhibitor, was similarly effective against allodynia, strongly suggest that differences in 
drug potency and therefore enzyme inhibition do not account for these results. 
Indeed, the doses of SC-560 and SC-236 selected for our experiments were 
comparable to those used by other laboratories. Intrathecal SC-560 (I-100ug) inhibited 
the behavioral responses of the formalin test (Yamamoto and Nozaki-Taguchi, 2002), 
substance P-induced hyperalgesia (Yaksh et aI., 2001). and a model of post-operative 
pain (Zhu et a1.. 2003). While Dirig et al. (1997) found 100jlg of SC-236 to be 
ineffective in reducing the rise in PGE2 concentration in spinal dialysate during the 
formalin test. Deleo et al. (2000) reported that 0.2mg/kg of SC-236 (approximately 
25Jlg/125g rat) alleviated nerve injury pain in an experimental model of radiculopathy. 
Likewise. the ibuprofen doses arc in line with those reported by others (Hall et al.. 1999; 
Dirig et aI., 1997). Thus. the choice of 1O-IOOjlg appears to be a reasonable dose range. 
especially considering that lOOOjlg exhibited no greater anti-allodynic effect than a 
100jlg-dose. 
We conclude that the difference in effect noted with SC-560 and SC-236 in the 
spinal nervc ligation model reflects the distinct contributions of COX-I and COX-2 in the 
emergence and early maintenance of tactile allodynia. respectively. 
S.2 COX EXPRESSION, COX ACTlVITV AND PG SYNTHESIS 
Preliminary results using Western analysis in our laboratory indicated detectable 
changes in spinal COX and NOS expression early after nerve injury. These results are in 
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agreement with earlier reports of changes in COX expression after spinal nerve ligation 
(Zhao et ai., 2000). While the data are consistent with the other results of the thesis 
research and support the overall working hypothesis, increased expression does not 
necessarily translate into changes in enzyme activity and, therefore increased PG 
synthesis. To address this issue directly, attempts were made to measure COX-I and 
COX-2 activity in spinal cord harvested from nerve-ligated and sham-operated rats using 
a commercially available kit (Cayman Chemical, product #760151). Unfortunately, 
efforts to eliminate background interference, thought to be caused by the high lipid 
content of spinal tissue, while retaining enzymatic activity proved unsuccessful. As a 
resuit, we were unable to generate reliable and reproducible COX activity data. 
In spite of this limitation, changes in COX levels are often used as indicators of 
increased prostanoid participation and are frequently correlated with cbanges in PG 
synthesis. For example, Eibl et al., (2003) reported a correlation between COX-2 
expression and both basal and arachidonic acid-stimulated PGE2 synthesis in pancreatic 
cells. Samad et al. (200t) also reported a correlation between PGE2 concentration in 
cisternal CSF samples and the spinal expression ofCOX-2 following inflammation in the 
hindpaw. Concurrent increases in COX-2 expression and COX-mediated PGE2 synthesis 
have also been reported in the spinal cord of rats with experimental diabetic neuropathy 
(Freshwater et ai., 2002). 
Whi le the inclusion of spinal COX activity data would have undoubtedly 
strengthened the connection between enhanced COX expression and spinal prostanoid 
synthesis early after spinal nerve ligation, we believe the body of evidence presented in 
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this thesis is sufficiently convincing to support further studies of this relationship, and its 
functional consequences in the establishment of allodynia. 
5.3 DISTINCT EFFECTS OF SPINAL COX-I AND COX-2 IN ALLODYNIA 
An interesting and important result arising from the present research is the 
differential role for COX-J and COX-Z in the allodynia following spinal nerve ligation. 
Considering the fact that both isoforms are constitutively expressed in the spinal cord, an 
obvious and related question is why the early inhibition of COX-l is more effective in 
preventing the emergence ofallodynia than that ofCOX-2. 
Studies with knockout mice expressing only COX-lor COX-2 indicate that each 
isozyme subserves particular physiological functions. For example, COX- J knockouts 
showed significantly impaired hemostatic function, which was not affectd by COX-2 
knockout. Also, COX-2 knockout mice developed renal impairments, and the females 
were infertile, although this infertilitiy was reversible by PGE2 treatment (DeWitt, 1999; 
Langenbach et ai., 1999). It has also been shown that cells expressing both isozymes ean 
selectively synthesize prostanoids through either pathway, suggesting a segregation of 
metabolic pathways (Kuwata et ai., 1998; Fujishima et al., 1999). This could be achieved 
through differential gene expression, and/or differences in the subcellular localization of 
each isozyme. Morita et al. (\995) showed COX-Z to be more concentrated in the 
nuclear envelope of murine 3T3 cells and human and bovine endothelial cells, while 
COX-J was equally distributed between the endoplasmic reticulum and nuclear envclope. 
This pattern raises the possibility that prostanoids originating from COX-l mediate their 
effects primarily through cell surface receptors, while products of COX-2 operate 
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primarily through nuclear receptors. However. the subcellular distribution of these 
isozymes also appears dependent upon the cell type. For example. in ORG cells. COX-I 
is found in the cytoplasm and nuclear membrane as well as axonal processes (Willingale 
et al.. 1997). 
Another explanation for the segregation of COX-I and COX-2 activity and 
function arises from the differences in their individual kinetics. Studies using many cell 
types (including macrophages and mast cells) have shown that when these are stimulated 
with cytokines or lipopolysaccharide, there is an initial burst in prostanoid synthesis that 
is mediated by COX-I, lasts for 10-30 min, and is associated with high concentrations of 
arachidonic acid. This is followed by delayed prostanoid synthesis which is catalyzed by 
COX-2 and is associated with lower concentrations of arachidonic acid (see review, 
Smith et aI. , 2000). Interestingly, while low concentrations of arachidonic acid (e.g. < I 
~) favor prostanoid synthesis via COX-2. high concentrations (e.g. >10 ~M) shunt 
production through the COX-I pathway (Murakami et aI., 1999). They reported that 
concentrations of arachidonic acid greater than 25 ~ resulted in a 5-fold increase in 
PGE2 in cells only expressing COX-l as compared to cells only expressing COX-2. This 
differential catalytic activity was also observed in cells expressing both isozymes 
concurrently (Kuwata et al.. 1998; Murakami et al. 1994). 
lonophore-based cell stimulation is known to produce non-specific activation of 
Ca2+ -dependent phospholipases. This, in tum, yields high intracellular concentrations of 
free arachidonic acid. The rapid and repetitive firing of injured nerves following spinal 
nerve ligation (Chaplan et ai, 2003; Han et a1. 2000) would be expected to generate a 
similar increase in arachidonic acid concentration in spinal cord neurons subject to this 
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afferent input. Based on the kinetic characteristics described above, this input would 
favour COX· I mediated PO synthesis immediately after nerve injury; a prediction 
consistent with the results of present research. In the days following injury, exaggerated 
atTerent input abates as other adaptations and response mechanisms (e.g. changes in gene 
expression, ion channel populations, receptor population density) take etTect (see review, 
Smith et aI., 2000). The intracellular concentration of free arachidonic acid presumably 
declines correspondingly and PO synthesis is shunted through the COX-2 pathway (see 
review, Smith et aI., 2000). This is also in agreement with the time course of COX-2 
mediated PO synthesis and allodynia fo llowing spinal nerve ligation. 
As yet another explanation for differential roles for COX-l and COX-2 could be 
based on the animals' age. Recent work by Ririe et al. (2004) suggests an age-dependent 
behavioral response to selective COX· I inhibitors, at least in the acute post-operative 
pain model of allodynia. If this is the case in the spinal nerve ligation model, it is 
possible that the efficacy of COX·! or COX-2 inhibitors might change as the animal 
ages. In fact this is an important issue considering the present results were obtained from 
pre·pubescent rats. The spinal nerve ligation model was originally described in young 
animals (4-6 weeks old; Kim and Chung, 1992), and it was reported that perfonning the 
nerve injury in young verses adult rats resulted in more robust tactile allodynia with 
greater consistency (Kim and Chung, 1992). It was for these reasons that the young 
animals were used in the present study. However, others have successfully used older 
rats, but with seemingly different absolute values for withdrawal thresholds (Zhu and 
Eisenach,2003). If there are in fact age-dependent behavioral responses to the isozyme-
selective COX inhibitors, and apparent age-dependent differences in development of 
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allodynia, an important issue is raised - that is, are the mechanisms surrounding the 
development and maintenance of allodynia in young rats different than that in adult rats. 
Attributing any or all of these possibilities (i.e. gene expression, isozyme kinetics, 
subcellular distribution patterns) to the differential effects of COX-I and COX-2 early 
after spinal nerve ligation will obviously require further investigation. Nevertheless, 
these diverse studies provide feasible explanations and documented evidence of 
differential COX-I and COX-2 mediated PG synthesis even within the same cell under 
conditions comparable to those expected after nerve injury. 
5.4 REQUIREMENT FOR ALTERED AFFERENT DRIVE IN THE 
DEVELOPMENT OF ALLODYNIA 
The application of tight ligatures to the peripheral segment of the L51L6 spinal 
nerves in the juvenile rat elicits a cascade of central neurochemical events that enable the 
miscoding of low-threshold input from the affected dermatome as a nociceptive event 
(i.e. aUodynia). One of the early, critical steps in this cascade is the abnormal synthesis 
of spinal PG, especially PGE2, followed by enhanced pharmacodynamic sensitivity to 
their effects in the affected spinal cord. These central responses to peripheral nerve 
injury, which underlie the emergence of an allodynie state, must be triggered by altered 
afferent drive into the spinal cord. Indeed, there is ample evidence that spinal PG 
synthesis is extensively regulated by neuronal input and mediated by glutamate operating 
through spinal NMDA receptors (Dirig and Yaksh, 1999). Thus, blocking input from 
injured nerve fibers should prevent, or at the very least disrupt the development of 
allodynia, including the synthesis of spinal PG. 
116 
Indeed, this has been tested in the spinal nerve ligation model previously. Abdi et 
al. (2000) applied lignocaine (2%) or bupivicaine (0.5%) solution directly to L5 and L6 
spinal nerves for 10 min prior to nerve ligation. A separate experiment was also 
conducted in which local anesthetic was applied 4 d after ligation. Neither treatment 
prevented development of NP. This is not surprising given the relatively short duration 
of nerve blockade (single dose). Moreover, the results of this thesis research indicate that 
phannacological treatment after nerve injury must be sustained for a minimum period of 
time (at least 8 h with i.t. COX inhibitors) if any effect on developing NP is to be 
achieved. While the exact duration of nerve blockade using local anesthetics is unknown 
in this model, the expected duration of action following the topical application of local 
anesthetics used by Abdi et aL (2000) appears to be insufficient in this model. 
A more comprehensive study of altered afferent drive following nerve injury was 
perfonned by Suter and colleagues (2003). Using the spared-nerve injury model, they 
applied bupivicaine directly to the sciatic nerve, proximal to the site of injury, using 
microspheres thereby providing slow release of the anesthetic over several days. 
Interestingly, nerve block that was present before and up to 6-10 days after nerve injury 
(con finned by sensory-motor testing) failed to prevent development of NP, suggesting 
that blockade of afferent input may only delay development ofNP. While this may seem 
contradictory to the theory formulated in this thesis, there are at least two possible 
explanations for this. Firstly, a different model ofNP (i.e. the spared-nerve injury model) 
was used in the study by Suter et al. (2003) whose pathophysiological mechanisms are 
likely to differ from those of L51L6 spinal nerve ligation. Indeed, the pharmacological 
profile of this model is different than that of other animal models, particularly the spinal 
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nerve ligation model. For example, Decosterd et al. (2004) and Erichsen and Blackbum-
Munro (2002) reported the tactile allodynia in the spared-nerve injury model to be 
insensitive to MK-801, an agent that is known to be effective in temporarily reversing 
tactile allodynia in the spinal nerve ligation model (Lee and Yaksh, 1995). Secondly, 
application of local anesthetics to peripheral nerves may itself cause nerve damage (see 
review, Borgeat and Ekatodramis, 2001). Suter and colleagues did not conduct any 
ultrastructural examination of the targeted nerve after anesthetic blockade to eliminate the 
possibility of this confounding effect. Clearly, the issue of and dependency on altered 
afferent drive to trigger early central adaptations that manifest as NP, including allodynia, 
require further and better investigation. 
5.5 PROSTAGLANDINS ARE BIOLOGICALLY ACTIVE AT VERY LOW 
CONCENTRATIONS 
Even under nonnal conditions, prostaglandins are known to effect biological 
responses at exceptionally low concentrations, and discrepancies between their effective 
concentrations and Kd values in experimental preparations are not uncommon. For 
example, iloprost induced increases in cAMP in Chinese hamster ovary (CHO) cells 
transfeeted with IP receptors at an ECso of 100 pM (Namba et al., 1994). PGE2 decreased 
cAMP production in EP3-transfected CHO cells with an ICso of 100 pM (Sugimoto et ai, 
1993). These values are at least 30-45 fold lower than the reported binding affinities at 
their respective prostanoid receptors. Similarly, PGE2 inhibited cAMP levels and 
antagonized the actions of vasopressin in canine cortical collecting tubules at picomolar 
concentrations (Garcia-Perez and Smith, 1984). 
118 
Differences have also been reported in the efficiency of signaling by different 
transduction mechanisms coupled to the same receptor. While picomolar concentrations 
of iloprost initiated cAMP production at the IP receptor, phosphatidylinositol turnover 
required concentrations of iloprost three orders of magnitude higher (Narumiya et aI., 
1999). Variations in coupling efficiency at the IP receptor have bcen reported in platelets 
from many species (Armstrong et aI., 1989). Taken together, these reports suggest that 
prostaglandins can elicit responses even at concentrations well below their reported Kd 
values, even though the mechanism of this phenomenon remains unclear. Preliminary 
experiments in our laboratory suggest one possibility: prostaglandin-driven prostaglandin 
synthesis, or the ability of exogenous PGE2 to sufficiently increase cell activity to 
activate further prostaglandin synthesis. We have noted this both in vitro and in vivo. 
Firstly, when PGE2 was applied to spinal cord slices, a concurrent assay of bath 
media for glutamate and PGE2 resulted in the well-documentated increase in glutamate 
concentration (see chapter 3), but also an unexpected increase in bath concentration of 
PGE2 - indeed a concentration higher than that applied to the tissue (personal 
communication, D. O'Rielly and C. W. Loomis). This appears to depend on COX 
activity since incubation of the tissue with S(+)-ibuprofen significantly reduced the 
increases in bath concentration of both glutamate and PGE2 (personal communication, D. 
O'Rielly and C. W. Loomis) Secondly, a similar result was found in vivo, when the 
pretreatment of naive rats with i.t. S(+)-ibuprofen reduced i.t. PGErinduced allodynia 
(personal communication, J. Robinson and C. W. Loomis). Whether this effect is a direct 
action mediated by PGE2, through EP receptors and activation of COX, or a secondary 
effect mediated by the glutamate release from the cells first activated by PGE2, is 
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currently being investigated. Regardless, the result in both cases appears to be a higher 
concentration of PGE2 in contact with the tissue (whether in vitro or in vivo) than 
actually administered. This is yet another possible explanation of how the administration 
of pi co molar (or lower) concentrations ofPOE2 could appear to have cellular effects. 
5.6 SUMMARY 
The results of this thesis research affirm a role for spinal prostaglandins in the 
emergence and early expression ofbrush~evoked allodynia following L51L6 spinal nelVe 
ligation. In addition, they define the period after nelVe injury in which spinal prostanoid 
synthesis is critically important for development of allodynia, and characterize the nature 
of the interaction between PO and NO in this model ofNP. In tum, they raise a number 
of important questions which could be the subject of future studies. At what point after 
nelVe injury do COX inhibitors losc their anti~allodynic effcct? It seems they become 
ineffective about 14 days or later, but clearly, detailed experiments are needed to 
characterize this waning effect. What other spinal prostanoids are relevant in this model 
of allodynia? Two obvious possibilities are PGF211 and POl2 • both of which have been 
implicated in normal pain processing in the spinal cord. What prostaglandin receptor 
subtypes mediate the pro·allodynic effects of spinal PO, where are they localized in 
spinal dorsal hom, and on what cell types are they expressed? For example, all four EP 
receptor subtypes were shown to be over·expressed in the injured nelVe after partial 
sciatic nelVe ligation (Ma and Eisenach, 2003). Whether a similar effect and receptor 
profile occurs in the spinal cord after spinal nelVe ligation has yet to be determined. 
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Finally, the cellular mechanisms by which prostaglandins elicit these effects 
remain to be determined. These could include the direct activation of spinal neurons 
leading to central sensitization and hyperexcitability (Baba et aI., 2001). However, their 
effects on sensory processing are likely to be far more complex. For example, Ahmadi 
and collegues (2001) reported that PGE2 reduces glycine-mediated inhibition in rat spinal 
cord slices; this effect was further characterized by Harvey et al. (2004). This may be 
directly related to a recent report by Coull et al. (2003) who show that the reversal 
potential of the membrane currents evoked by glycine and GABA became more positive 
after peripheral nerve injury. As a result, physiological mechanisms normally 
suppressing lamina I neurons now amplified their output. Finally, the possible 
contributions of COX-3, a recently identified isoform whose physiological relevance 
remains unknown (Chandrasekharan et aI., 2002), in this model have not been 
investigated. These future studies will better define the role(s) of PG in allodynia, 
thereby contributing to more effective treatment strategies for humans, including the 
prevention of abnormal pain states collectively known as neuropathic pain. 
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